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1. Introduction 
 
1.1 Chromatin in eukaryotes 
 
The structure of chromatin plays an important role in the regulation of gene transcription, 
replication and DNA repair. In eukaryotic cells, the DNA is organized into long linear 
structures called chromosomes. DNA in combination with specialized proteins forms 
chromatin, which allows the long DNA molecules to fit into the cell nucleus. The basic repeat 
element of chromatin is the nucleosome, where 147 base pairs of DNA are wrapped around a 
histone octamer consisting of two molecules of each histone type, H2A, H2B, H3 and H4 
(Kornberg 1974; Luger et al. 1997). This structure is repeated every 200
€ 
±40 base pairs and 
forms a “beads-on-a-string” fibre structure with a diameter of 10 nm. With the addition of 
linker histone H1 in mammals (Contreras et al. 2003), the “beads-on-a-string” structure coils 
into a further condensed 30 nm-diameter helical structure known as the 30 nm fibre. 
 
1.2 Histone modifications 
 
Histone proteins consist of a globular domain and a more flexible, charged N-terminal region 
known as the histone tail. Histone tails are rich in lysine residues and are targets for covalent 
modifications, especially the strongly conserved histone tails of H3 and H4. Such 
posttranslational modifications are the acetylation, methylation and ubiquitination of lysine 
(K) residues, the methylation of arginines (R) and the phosphorylation of serine (S) and 
threonine (T) residues. These modifications regulate interactions with DNA and other 
proteins. They are deposited during cell cycle progression, DNA replication, DNA damage 
and repair and influence overall chromosome stability (reviewed in (Jenuwein and Allis 
2001)). Furthermore, histones can be sumoylated, with the consequence of transcriptional 
repression (Nathan et al. 2006). 
The acetylation status of histone proteins plays a role in protein-protein interactions, nuclear 
transport, DNA-binding affinity, and it alters gene transcription. The reversible acetylation of 
ε-amino groups of lysines in histone proteins neutralizes the positive charge and therefore 
weakens the interaction with the negatively charged DNA phosphate backbone. This allows 
different transcription factors to gain access to the promoters of target genes (reviewed in 
(Turner 1991)). This characterizes euchromatin, which is transcriptionally active and tends to 
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be hyperacetylated. Removal of acetyl groups from lysine residues results in stronger histone-
DNA contact and compaction of chromatin, called heterochromatin. This chromatin structure 
represses gene transcription and tends to be hypoacetylated (Braunstein et al. 1993). This 
histone modification depends on the activity of histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). 
 
1.3 Histone deacetylases 
 
HDACs are a group of enzymes that remove acetyl groups from a ε-N-acetyl lysine amino 
acid on histones. So far, there are eighteen different histone deacetylases known in humans. 
They are divided into four groups based on their functions and protein sequence similarity to 
yeast transcriptional repressors. Class I and class II are considered “classical” HDACs whose 
activities are inhibited by Trichostatin A (TSA). HDACs of class I (HDAC1, -2, -3 and -8) are 
homologues of the yeast transcription factor Rpd3 (reduced potassium dependency 3). They 
have a conserved structure and are located preferentially in the nucleus. Class II HDACs 
(HDAC4, -5, -6, -7, -9 and -10) are homologues of yeast Hda1 (histone deacetylase 1), and 
they are able to shuttle in and out of the nucleus, depending on different signals (de Ruijter 
AJ, 2003). HDAC11 is the only member of class IV HDAC that has characteristics of both 
class I and II. Class III HDACs are a family of nicotinamide adenine dinucleotide (NAD+)-
dependent histone deacetylases, so called sirtuins. In contrast to class I, II and IV they are not 
Zn2+-dependent, although a Zn2+-binding domain exists in the catalytic core domain, and they 
cannot be inhibited by TSA. 
 
1.4 Sirtuins 
 
The founding member of sirtuins is the yeast transcriptional repressor Sir2 (silent information 
regulator 2). It was originally identified in Saccharomyces cerevisiae as a factor involved in 
regulation of mating type (Rine and Herskowitz 1987). Meanwhile, more than 60 homologues 
of sirtuins have been found in plants, bacteria, vertebrates and invertebrates. Each sirtuin has 
a protein core domain of approximately 270 amino acids, and most of them contain NAD+-
dependent deacetylase activity. This catalytic core domain defines the sirtuin family, which is 
conserved from bacteria to eukaryotes (Frye 2000). In addition to the core domain, each 
sirtuin contains a unique N- and/or C-terminal region that varies in length and sequence. 
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1.4.1 S. cerevisiae homologue Sir2 
 
The discovery of the Sir2 protein from the budding yeast S. cerevisiae resulted from studies of 
how the yeast cell type, known as mating type, is regulated (Rine and Herskowitz 1987). 
Mating type in yeast is determined by a single locus, MAT, which regulates the sexual 
behaviour of both haploid and diploid cells. Haploid cells contain only one allele of MAT, 
MATa or MATα, which determines their mating type. MATa cells can mate only with MATα 
cells, which produces MATa/α diploid cells. Furthermore, yeast cells also contain two 
silenced copies of the mating type information, HML and HMR. The HML (homothallic 
mating left) locus carries a silenced copy of the α allele, and the HMR (homothallic mating 
right) locus carries a copy of the a allele.  
Sir2 is required for all known types of silencing in yeast: (I) repression of the mating-type loci 
HML and HMR, (II) telomeric repression, (III) rDNA silencing (reviewed in (Stone and Pillus 
1998)). Even though it is required at all three silenced regions, the repressive mechanism 
differs. At telomeric DNA regions and at the silent mating type loci, Sir2, together with Sir3 
and Sir4, builds the SIR complex, which is an essential structural component of 
heterochromatin. Additionally, at the HM loci, Sir1 is necessary for the SIR complex to 
assemble at the silencers. Sir2 deacetylates the histones H3 and H4 in a NAD+-dependent 
fashion and thereby creates new high-affinity binding sites for Sir3 and Sir4 at adjacent 
nucleosomes. They bind to the deacetylated tails of H3 and H4 as well as to unmethylated 
H3K79 and spread throughout the silent locus. At the ribosomal DNA locus (rDNA), Sir2, 
together with Net1 and Cdc14, builds the RENT complex (regulator of nucleolar silencing 
and telophase exit) to silence integrated reporter genes  (reviewed in (Rusche et al. 2003)). 
One reason of aging in yeast is the accumulation of circular species of rDNA, so-called 
extrachromosomal rDNA circles (ERCs). They are able to replicate and preferentially 
segregated to mother cells during cell division. As a result, aging mother cells accumulate 
vast amounts of ERCs (Sinclair and Guarente 1997). In 1999, it was shown that the addition 
of an extra copy of the SIR2 gene extend lifespan by suppressing rDNA recombination and 
decreasing ERC formation, while deletion of SIR2 has the opposite effect (Kaeberlein et al. 
1999). Also in Caenorhabditis elegans (Tissenbaum and Guarente 2001) and Drosophila 
melanogaster (Rogina and Helfand 2004) an extension of lifespan could be observed through 
increased dosage of a SIR2 gene. However, recent studies have called the effect of increased 
SIR2 dosage in both C. elegans and D. melanogaster to question (Burnett et al. 2011). 
Nonetheless, these findings have led to widespread interest in mammalian sirtuins. 
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1.4.2 Mammalian sirtuins 
 
The mammalian sirtuins consist of seven members, SirT1 to SirT7 (displayed in Figure 1.1). 
They can be localized in different cell compartments, have distinct substrates and a broad 
range of functions. Their expression level differs and can be modulate through different 
environmental or pathological conditions. Similar to the yeast transcription factor Sir2, some 
of them deacetylate histones, but several sirtuins also have targets such as enzymes or 
transcription factors that regulate stress, metabolism and survival pathways. Because of their 
sequence similarity, they are divided into subgroups. Class I sirtuins including SirT1 to SirT3 
have a robust deacetylase activity compare to the other sirtuins, which have either no 
detectable or very weak deacetylase activity. Class II comprises only SirT4 and Class III only 
SirT5, whereas SirT6 and SirT7 belong to Class IV (Frye 2000). 
 
 
Figure 1.1: Schematic view of human sirtuins 
The illustration shows the domain architecture of human sirtuins (SirT1-SirT7) and their intracellular 
localization. The NAD+-dependent conserved catalytic core domain (yellow) is flanked by variable N- and C-
terminal segments. Zn2+-binding domains (black) are located in the catalytic core domain. The picture is 
modified from (Rajendran et. al, 2011). 
 
SirT1 is the closest homolog of the Sir2 protein of S. cerevisiae (Voelter-Mahlknecht and 
Mahlknecht 2006), and it is the best-characterized mammalian sirtuin so far. It plays an 
important role in many biological processes like cancer development, calorie restriction and 
aging associated diseases. SirT1 is mainly located at the nucleus, but apart from 2 NLSs 
(nuclear localisation signal), it also contains 2 NES (nuclear export signal) domains. Through 
these domains, SirT1 can shuttle between the cytoplasm and the nucleus (Tanno et al. 2007). 
The nuclear-cytoplasmic distribution and enzymatic activity of SirT1 is regulated by different 
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modifications. For instance, JNK (c-Jun N-terminal kinase) interacts directly with SirT1 upon 
oxidative stress and phosphorylates SirT1 at Ser27, Ser47 and Thr530, thereby enhancing its 
nuclear localisation and enzymatic activity (Nasrin et al. 2009). In contrast to this, mTOR-
dependent phosphorylation of Ser47 alone results in inhibition of SirT1 deacetylase activity 
(Back et al. 2011). All in all, Sasaki et al. identified 13 phosphorylation sites on SirT1, which 
are located in the N- and C-terminal region. Two of these sites, Thr530 and Ser540, are 
substrates of CDK (cyclin B/cyclin-dependent kinase 1) complexes. Further analyses show 
that phosphorylation of these two sites are required for normal cell cycle progression (Sasaki 
et al. 2008). In murine SirT1, four more phosphorylation sites of protein kinase CK2 were 
identified, whereby two of them were also described in human SirT1 at the corresponding 
amino acids Ser659 and Ser661 (Kang et al. 2009; Zschoernig and Mahlknecht 2009). Ser659 and 
Ser661 lie within the ESA (essential for SirT1 activity) motif of SirT1, which comprises a 
small region from amino acids 641-665 (Kang et al. 2011). ESA interacts with the catalytic 
core domain, activates the catalytic activity and increases the affinity for substrates.  
The binding site of ESA in the catalytic core domain is also the interaction site of DBC1 
(deleted in breast cancer 1), the endogenous inhibitor of SirT1 (Kim et al. 2008). It is possible 
that the two phosphorylation sites within ESA modulate the interaction of the C-terminaus 
with the catalytic core domain, and thereby control the SirT1 activity and substrate 
recognition through an allosteric mechanism (Flick and Luscher 2012).  
In addition to phosphorylation, SirT1 is modified by sumoylation, which increases catalytic 
activity. SUMO is a small ubiquitin-related protein that can be attached to the C-terminal end 
of SirT1 at Lys734. Upon stress, SirT1 becomes associated with the nuclear desumoylase 
SENP1, which reduces SirT1 activity and promotes p53 activation and cell death (Yang et al. 
2007). The mechanism is not fully understood, but it is suggested that the sumoylation 
enhances the interaction of ESA with the catalytic core domain (Flick and Luscher 2012).  
Liu et al. identified an additional modification of SirT1. The methyltransferase Set7/9 
interacts with and methylates SirT1 at Lys233, Lys235, Lys236 and Lys238 of the N-terminal 
region. It is currently not known whether the methylation of SirT1 affects its activity, but the 
interaction of Set7/9 with SirT1 disrupts the binding of SirT1 with p53. Thus, p53 remain 
acetylated and in the activated state (Liu et al. 2011).  
Furthermore, nuclear SirT1 is transnitrosylated by nitrosylated GAPDH at two cysteines, 
Cys387 and Cys390, within the catalytic core domain. Upon nitrosylation of SirT1, an increase 
of acetylated PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 
1-alpha), a substrate of SirT1, was observed. This indicates that the deacetylase activity of 
SirT1 is inhibited by nitrosylation (Kornberg et al. 2010).  
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As mentioned above, the expression level is tissue-specific and can be influenced by 
environmental conditions. For example, SirT1 is up-regulated by calorie restriction (CR), 
external cold temperature or oxidative stress (Cohen et al. 2004; Crujeiras et al. 2008). It is 
also up-regulated in different cancer cells such as murine and human lung caner, prostate 
cancer, leukaemia, lymphomas and colon cancer compare to the normal tissue (Lim 2006; 
Fraga and Esteller 2007; Stunkel et al. 2007). Furthermore, Kim et al. have shown that SirT1 
and AROS (active regulator of SirT1) are co-expressed in nearly equal amounts in the 
majority of cancer cell lines that were screened, suggesting that AROS might be a tumour cell 
survival factor and maybe a target for tumour therapy (Kim et al. 2007b). Intriguingly, SirT1 
protein level was also found reduced in some cancer types, including various forms of ovarian 
cancers, prostate carcinoma, bladder carcinoma and glioblastoma (Wang et al. 2008). 
Similar to the yeast Sir2, SirT1 mediates heterochromatin formation through deacetylation of 
the histone tails (H1K26, H3K9 and H4K16) and through recruitment and deacetylation of H1 
(Vaquero et al. 2004). Further, SirT1 modifies histones indirectly through deacetylation of the 
histone acetylase p300, which is sumoylated and rapidly degraded upon lysine deacetylation 
(Bouras et al. 2005). The acetylase p300 is a rate-limiting co-activator for a broad range of 
transcription factors. SirT1 also deacetylates a number of important transcription factors, most 
importantly p53 (Vaziri et al. 2001). The tumour suppressor p53 is acetylated and activated in 
response to cellular stress and DNA damage, and induces cell death. The deacetylation of p53 
by SirT1 inactivates its transcriptional activity and therefore promotes cell survival. Further 
substrates of SirT1 are members of the forkhead box O (FOXO) family (Brunet et al. 2004). 
These transcription factors are homologs of C. elegans DAF-16 and regulate several 
mammalian cell functions, including cell metabolism and cell cycle progression. As for p53, 
the deacetylation of FOXO by SirT1 inhibits its transcriptional activity and promotes cell 
survival. SirT1 also deacetylates and inhibits the transcription factor NF-κB, a master 
regulator of inflammatory processes (Yeung et al. 2004). Furthermore, SirT1 interacts with 
several components of the DNA repair machinery such as NBS1 and Ku70 (Cohen et al. 
2004; Yuan et al. 2007; Li and Luo 2011). Whereas NBS1 operates in the homologous 
recombination pathway of double-strand break (DSB) repair, Ku70 operates in the non-
homologous end-joining (NHEJ) pathway. 
 
SirT2 is expressed in at least two isoforms, a longer variant consisting of 389 amino acids 
and a shorter variant of 352 amino acids (Voelter-Mahlknecht et al. 2005). In contrast to 
SirT1, SirT2 is predominantly localized in the cytoplasm and co-localizes with microtubules, 
but it can also be found in the nucleus (North et al. 2003; Bae et al. 2004). North et al. 
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identified a Crm-1 dependent NES domain located in the N-terminus of SirT2, and through 
this domain it is actively exported from the nucleus. Although they were unable to identify a 
functional NLS domain, they could show that SirT2 constantly shuttles between nucleus and 
cytoplasm during interphase. During G2/M transition and in mitosis, SirT2 is predominantly 
nuclear or chromatin-associated. Additionally, SirT2 is hyperphosphorylated during G2/M 
transition and in M phase, which correlates with the nuclear translocation of SirT2 (Dryden et 
al. 2003; North and Verdin 2007). This suggests that Cyclin B/CDK1 and other mitosis-
specific kinases regulate the cell cycle-dependent nuclear localisation (Flick and Luscher 
2012). So far, two phosphorylation sites are known on SirT2 (long and short variant), 
Ser368/331 and Ser372/335, which are located in the C-terminal region (Nahhas et al. 2007). 
Ser368/331 is part of a Cyclin/CDK consensus motif and has been identified as a substrate of 
Cyclin B/CDK1, Cyclin E/CDK2, Cyclin A/CDK2, Cyclin D3/CDK4 and p53/CDK5 (North 
and Verdin 2007; Pandithage et al. 2008). Phosphorylation of SirT2 at Ser368/331 reduces its 
deacetylase activity and occurs when cells enter S phase, suggesting that this modification 
does not play a role in nuclear accumulation of SirT2 (Pandithage et al. 2008). So far, nothing 
is known about the phosphorylation at Ser372/335, neither the responsible kinase nor the 
influence on SirT2 function (Flick and Luscher 2012). A further modification of SirT2 is the 
acetylation by the HAT p300. Although this modification has not been mapped, it interferes 
with the catalytic activity of SirT2 (Han et al. 2008).  
One important target of SirT2 is lysine 40 of α-tubulin both in vitro and in vivo. Tubulin 
regulates different cellular events such as mitosis, cellular organisation, transport and motility. 
Acetylated tubulin is abundant in stable microtubules, but is absent in dynamic cellular 
structures, thus the acetylation status of α-tubulin serves as a marker for the presences of 
stable microtubules (Piperno et al. 1987; Robson and Burgoyne 1989). It was shown that 
knockdown of endogenous SirT2 via siRNA results in hyperacetylation of α-tubulin. Despite 
the fact that SirT2 co-localises and interacts with HDAC6, another tubulin deacetylase, SirT2 
is a bona fide tubulin deacetylase (North et al. 2003). However, the group of G. Bates has 
recently shown that reduction or loss of SirT2 has no effect on the acetylation of α-tubulin in 
the brains of wild type mice. Therefore, they postulate that HDAC6, and not SirT2, is the 
major tubulin deacetylase in the brain (Bobrowska et al. 2012).  
Furthermore, SirT2 deacetylates the histone tails H4K16, H3K9 and H3K56 (Vaquero et al. 
2006; Vempati et al. 2010). It has been hypothesized that SirT2 functions in mitotic 
regulation, because SirT2 deacetylates H4K16 at a global level during mitosis, which may 
facilitate the generation of condensed chromatin (Vaquero et al. 2006). However, the loss of 
Hst2, a yeast homologue of SirT2, does not affect viability, and SirT2 knockout mice also 
Introduction 
 12 
seem to be normal (Perrod et al. 2001; Kim et al. 2011). Similar to SirT1, SirT2 also 
deacetylases the forkhead transcription factors FOXO1 and FOXO3a (Wang et al. 2007; 
Wang and Tong 2009) and the tumour suppressor p53 (Peck et al. 2010). Therefore, SirT2 is 
also connected with multiple cellular processes such as cell cycle progression, apoptosis, 
metabolism and aging. Furthermore, SirT2 is suspected to play a role in blood glucose 
homeostasis by deacetylating and stabilizing the phosphoenolpyruvate carboxykinase 1 
(PEPCK1), which is an important enzyme in gluconeogenesis (Jiang et al. 2011). When SirT2 
is activated by low glucose conditions, PEPCK1 becomes deacetylated and stabilized, and 
enhances the gluconeogenesis, which is the generation of glucose from non-carbohydrate 
carbon substrates such as pyruvate and lactate.  
 
SirT3 is one of three sirtuins that are located in the mitochondria (Michishita et al. 2005). It is 
present in the mitochondrial inner membrane (Onyango et al. 2002; Schwer et al. 2002; 
Lombard et al. 2007). Two distinct isoforms of SirT3 are known. A long form of 
approximately 44 kDa contains an NH2-terminal cleavable presequence, a so-called 
mitochondrial localization sequence (MLS), which is important for the mitochondrial import. 
This long isoform is synthesized as an inactive precursor within the cytoplasm. Upon 
translocation into the mitochondria, SirT3 is cleaved at arginines 99/100 by MPP (matrix 
processing peptidase) to the short isoform of 28 kDa. This proteolytic cleavage of SirT3 
activates its NAD+-dependent deacetylates activity (Schwer et al. 2002; Jin et al. 2009; Bao et 
al. 2010). Six phosphorylation sites of SirT3 have been identified, between amino acid 101 
and 118 (Olsen et al. 2010), but their biological function or influence on SirT3 has not been 
analyzed yet. Due to the fact that the phosphorylation sites are close to the mitochondrial 
cleavage site, it is possible that they modulate the SirT3 enzyme activity (Flick and Luscher 
2012).  
Analysis of the acetylation status of mitochondrial proteins in SirT3, SirT4 and SirT5 
knockout mice showed that SirT3 is the main deacetylase in mitochondria (Lombard et al. 
2007). SirT3 has a large number of important mitochondrial proteins as substrates, for 
instance subunits of oxidative phosphorylation complexes (Ahn et al. 2008), metabolic 
enzymes such as acetyl-CoA synthetase 2 (Hallows et al. 2006; Schwer et al. 2006), long-
chain acyl CoA dehydrogenase (LCAD) (Hirschey et al. 2010) and 3-hydroxy-3-
methylglutaryl CoA (HMG-CoA) synthase 2 (Shimazu et al. 2010), as well as the oxidative 
stress reducing enzymes isocitrate dehydrogenase 2 (IDH2) (Someya et al. 2010), superoxide 
dismutase 2 (SOD2) (Qiu et al. 2010) and manganese superoxide dismutase (MnSOD) (Tao et 
al. 2010). Because of this large number of substrates, SirT3 is associated with diverse 
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metabolic processes such as ATP production, energy metabolism, fatty acid oxidation, 
ketogenesis and the urea cycle. Furthermore, it was shown that SirT3 functions as a tumour 
suppressor in response to stress (Kim et al. 2010), and it can delay the onset of a number of 
oxidative stress-mediated pathologies in multiple tissues (Qiu et al. 2010; Someya et al. 
2010). All observations so far suggest that SirT3 may be a novel target for age-associated 
diseases as well as aging itself, but much work is needed to completely understand the 
function of SirT3. 
 
SirT4 is another sirtuin located in the mitochondria (Michishita et al. 2005). It is the sole 
sirtuin that has no detectable NAD+-dependent deacetylase activity. Only an ADP-
ribosyltransferase activity is known. Similar to SirT3 and other typical mitochondrial matrix 
proteins, SirT4 is proteolytically processed to remove the N-terminal 28 amino acids upon 
translocation into the mitochondria (Ahuja et al. 2007). In contrast to SirT3, it is not known 
whether this proteolytic cleavage of SirT4 influences its enzymatic activity. In SirT4, three 
phosphorylation sites have been identified at Ser255, Ser261 and Ser262 (Yu et al. 2007). 
However, no functional relevance has been determined yet. 
Very little is known about the functions of SirT4, but in SirT4 knockout mice an increased 
insulin secretion in response to glucose and amino acids was observed. Through its ADP-
ribosylation activity, it represses the activity of glutamate dehydrogenase (GDH), which 
promotes insulin secretion (Haigis et al. 2006). Ahuja et al. identified two additional targets 
of SirT4, insulin-degrading enzyme (IDE) and the ADP/ATP carrier protein adenine 
nucleotide translocator (ANT), which support the role of SirT4 in the control of insulin 
secretion in pancreatic β-cells (Ahuja et al. 2007).  
 
SirT5 is the third mitochondrial sirtuin located in the intermembrane space. Two 
transcriptional splice variants of SirT5 exist, which encode proteins with distinct C-terminal 
regions. Similar to SirT3 and SirT4, both isoforms are cleaved after the first 36 amino acids 
upon entry into the mitochondria (Michishita et al. 2005; Nakamura et al. 2008). The cleaved 
shorter isoform seems to be exclusively in the mitochondria, in contrast to the longer isoform, 
which is additionally found in the cytoplasm. The reason for this could be the different 
C-terminal regions of the two isoforms. The short isoform has a hydrophobic C-terminus and 
functions as a mitochondrial membrane insertion signal (Matsushita et al. 2011). So far, no 
posttranslational modifications on SirT5 are known. SirT5 has only weak deacetylase activity 
and was recently identified as a protein lysine desuccinylase and demalonylase (Du et al. 
2011). Du et al. have shown that the catalytic efficiencies for demalonylation and 
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desuccinylation were much higher (29- to >1000-fold) than that for deacetylation. The reason 
for this phenomenon is an arginine residue (Arg105) and tyrosine residue (Try102) in the active 
site of SirT5, which interact with succinyl and malonyl groups. Du et al. identified several 
mammalian proteins that carry succinyl or malonyl lysine modifications (Du et al. 2011).  
It has furthermore been shown that SirT5 binds and deacetylases carbamoyl phosphate 
synthetase (CPS1), which catalyses the rate-limiting and first step of the urea cycle. SirT5 
knockout mice show increased acetylation of CPS1 and elevated levels of ammonia after 
prolonged fasting, whereas SirT5 overexpression in mice leads to increased CPS1 activity 
(Nakagawa et al. 2009; Ogura et al. 2010). Du et al. identified three lysine residues on CPS1 
that are both acetylated and succinylated (Lys44, Lys287 and Lys1291). Additionally, it was 
shown that the succinylation level of Lys1291 increases dramatically in SirT5 knockout mice in 
comparison to wild-type mice (Du et al. 2011).  
 
SirT6 is a broadly expressed nuclear protein with deacetylase activity, but robust auto-ADP-
ribosyltransferase activity (Liszt et al. 2005). Tennen et al. showed that the conserved core 
domain of SirT6 alone is not sufficient for the deacetylase activity, but that it requires the 
N-terminal region. Thus is similar to other sirtuins, which require either N- or C-terminal 
regions to activate catalytic function. In the C-terminal region, two phosphorylation sites at 
Tyr294 and Ser303 were identified (Dephoure et al. 2008), but their influence on SirT6 function 
still needs to be determined. Furthermore, an NLS signal between amino acids 345 and 351 in 
the distal region of the C-terminal has been identified (Tennen et al. 2010).  
Human SirT6 was characterized as a NAD+-dependent H3K9Ac deacetylase that modulates 
telomeric chromatin. Its depletion leads to telomere dysfunction with end-to-end 
chromosomal fusions and premature cellular senescence (Michishita et al. 2008). Under 
physiologic conditions, SirT6 interacts with the transcription factors NF-κB and HIF1α, and 
is transported to their target gene promoters, where it deacetylates H3K9Ac or H3K56Ac 
(Kawahara et al. 2009; Yang et al. 2009). SirT6 binds to many promoters, which are highly 
enriched for NF-κB, SP1, STAT1/3, ELK1, E2F1 and FOXO1/4 binding motifs (Kawahara et 
al. 2011). As a result, SirT6 seems to have widespread activities as a regulator of transcription 
of genes involved in glucose and lipid metabolism. Additionally, SirT6 has been established 
as a key component of base excision repair (BER). It directly stabilises DNA-dependent 
protein kinase at the site of dsDNA breaks. This allows the formation of the DNA repair 
complex and the initiation of repair mechanism (McCord et al. 2009).  
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SirT7 is a widely expressed nucleolar protein that is associated with active ribosomal RNA 
(rRNA) genes and histones (Michishita et al. 2005). It is proposed to be an active regulator of 
RNA polymerase I (Pol I) and therefore required for cell viability in mammals. Its expression 
level correlates with growth, it is abundant in tissues with high proliferation, such as liver and 
spleen, and absent or low in non-proliferating tissues like heart, brain and muscle (Ford et al. 
2006). It is suggest that SirT7 is phosphorylated during mitosis by a CDK complex, but 
neither have any sites been mapped, nor are any functional consequences known (Grob et al. 
2009). 
Indirect evidence has led to the assumption that SirT7 deacetylates the tumour suppressor p53 
(Vakhrusheva et al. 2008), but this has not been confirmed so far. Recent data have shown 
that SirT7 has a specific NAD+-dependent H3K18Ac deacetylase activity (Barber et al. 2012). 
Previously it was shown that low levels of H3K18Ac predict a higher risk of prostate cancer 
recurrence and poor prognosis in lung, kidney and pancreatic cancers (Manuyakorn et al. 
2010).  
 
1.4.3 Deacetylation reaction of sirtuins 
 
Although sirtuins have been known for many years, their deacetylation activity was many 
years after their initial discovery. Studies of the Salmonella Sir2-like protein (CobB) gave the 
first hint that Sir2-like proteins are ADP-ribosyltransferases, because they transfer ADP-
ribose from NAD+ to substrate molecules (Tsang and Escalante-Semerena 1998; Frye 1999). 
From there, several studies followed showing that Sir2-like proteins also have a NAD+-
dependent histone deacetylase activity (Imai et al. 2000; Landry et al. 2000; Smith et al. 
2000). In contrast to the classical zinc-dependent histone deacetylases, sirtuins cleave the 
nicotinamide ribosyl bond of NAD+ and transfer the acetyl group from proteins to their 
cosubstrate NAD+. This generates deacetylated protein, nicotinamide (NAM) and 2´-O-acetyl-
ADP-ribose (O-AADPr) (Tanner et al. 2000; Tanny and Moazed 2001; Lee et al. 2008) 
(Figure 1.2). Two different possible mechanism of deactylation reaction are discussed, an 
SN1- or an SN2-like reaction, but recent evidence strongly supports the SN2-like mechanism. 
In the first chemical step, the acetyl oxygen undergoes nucleophilic attack of the 1`-carbon of 
the nicotinamide ribose to form an O-alkylamidate intermediate through elimination of NAM. 
Subsequently, the 2`-hydroxyl of the nicotinamide ribose is activated by an active-site 
histidine for attack of the O-alkylmediate carbon, forming a 1`, 2`-cyclic intermediate (Sauve 
et al. 2006; Smith and Denu 2006). The reaction occurs in a highly conserved region of 
sirtuins. Crystallographic studies indicate that bound acetyl-lysine changes the NAD+ 
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conformation and forces the nicotinamide ring of NAD+ deep within a conserved hydrophobic 
pocket, the so-called C-pocket. This forms a more reactive conformation of NAD+ (Avalos et 
al. 2004; Zhao et al. 2004b). The elimination of deacetylated protein followed by water 
addition generates a mixture of 2`- and 3`-O-Acetyl-ADP-ribose, whereby 3`-O-Acetyl-ADP-
ribose is formed by intramolecular transesterification (Sauve et al. 2001; Jackson and Denu 
2002). It is thought that these two unique metabolites (2`- and 3`-O-AADPr) play an 
important role in cell signalling and metabolism (Borra et al. 2002; Kustatscher et al. 2005; 
Grubisha et al. 2006). 
 
 
Figure 1.2: Deacetylation reaction of sirtuins 
Sirtuins deacetylate NAD+-dependent acetylated lysine residues to form nicotinamide (NAM), O-acetyl-ADP-
ribose (O-AADPR) and deacetylated protein. The reaction occurs in a highly conserved region of sirtuins and 
can be inhibited by NAM, which reacts with the intermediate and regenerate NAD+. NAM is also recycled back 
to NAD+ in further different mechanism. In yeast, worms and flies the reaction is catalyzed by PNC1 (nicotinate 
phosphoribosyltransferase) and in mammals by NAMPT (NAM phosphoribosyltransferase). Both enzymes can 
be influenced by environmental stress. (Haigis and Sinclair 2010) 
 
Furthermore, it was reported that sirtuins are inhibited by NAM, the endogenous sirtuin 
inhibitor (Bitterman et al. 2002; Sauve and Schramm 2003). It reacts with the O-alkylamidate 
intermediate and regenerates NAD+. It is thought to be a major mechanism for in vitro control 
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of sirtuin activity. NAM can also be recycled back to NAD+ in further different reactions. In 
yeast, worms and flies, the first step is catalyzed by Pnc1 (nicotinate 
phosphoribosyltransferase) to produce nicotinic acid. In the case of environmental stress, such 
as heat or calorie restriction (CR), Pnc1 is up-regulated, and this leads to increased stress 
resistance and life span extension in S. cerevisiae and D. melanogaster (Anderson et al. 2003; 
Gallo et al. 2004; Balan et al. 2008). Thus, it seems that Pnc1 promotes survival and life span 
in response to environmental stress. In mammals, the first step is catalyzed by NAM 
phosphoribosyltransferase, known as NAMPT, which converts NAM to nicotinamide 
mononucleotide (Rongvaux et al. 2002; Revollo et al. 2004). Consistent with the ability of 
Pnc1 to regulate Sir2 in yeast, mammalian NAMPT is one of the main regulators of sirtuin 
activity (Yang et al. 2006). 
 
1.4.4 Structural characteristics of sirtuins 
 
Most of the information on the structure of the catalytic core domain of sirtuins and its 
binding to ligands was obtained from crystallographic studies of the archaeal sirtuins, Sir2Af1 
(Garcia-Salcedo et al. 2003) and Sir2Af2 (Avalos et al. 2002; Avalos et al. 2004; Avalos et al. 
2005), human SirT2 (Finnin et al. 2001), yeast Hst2 (Zhao et al. 2003b; Zhao et al. 2004b) 
and the bacterial sirtuins, cobB (Zhao et al. 2004a) and Sir2Tm (Avalos et al. 2005).  
The catalytic core domain of sirtuins consists of two characteristic domains (Figure 1.3). The 
larger domain (residues 53-89, 146-186 and 241-356 of SirT2) is a variant of the Rossmann 
fold, the classic pyridine dinucleotide binding fold, which is present in many diverse 
NAD(H)/NADP(H) binding enzymes (Rossmann and Argos 1978). The smaller domain is 
composed of two structural modules (residues 90-145 and 187-240 of SirT2) that result from 
two insertions within the Rossmann fold domain. One module contains a structural zinc atom 
coordinated by four cysteine residues, which has the same topology as the RING finger motif 
and mediates protein-protein interactions. The other module forms a helical module that 
includes a small groove, lined with hydrophobic residues, that intersects the large groove. 
This small groove forms a pocket that may be a class-specific binding site for a protein, 
possibly recognizing portions of the substrate. The large groove partially corresponding to the 
large domain contains residues (Gly84, Gly86, Arg97, Gln167, Asn168, Asp170 and His187 of 
SirT2) invariant across the Sir2 family members and includes the NAD+ binding site. 
Mutations of these residues disrupt the deacetylase activity of sirtuins, suggesting that the 
large groove is the catalytic site (Finnin et al. 2001). This NAD+ binding pocket can be 
divided into three regions: site A, where the adenine-ribose moiety of NAD+ is bound; site B, 
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where the nicotinamide-ribose moiety is bound; and site C, which is deep inside the pocket 
and is directly involved in catalysis (Min et al. 2001). Furthermore, it has been proposed that 
the N-terminal extension is not required for the deacetylase activity in vitro (Finnin et al. 
2001).  
 
 
Figure 1.3: Structure of human SirT2 
The picture shows two views of the structure of human SirT2 catalytic core domain rotated by 90 °. SirT2 
consists of two domains, which are connected by several loops. The loops, which are the major structural 
components of the large groove (left panel; yellow), connect the small and large domain. The large NAD+ 
binding domain consists of a Rossmann fold domain (right panel; dark blue). The small domain contains two 
modules; one (right panel; gray) binds a zinc-atom (right panel; magenta) and the other (right panel; red) forms a 
helical module and contains a hydrophobic pocket. (Finnin et al. 2001) 
 
1.5 Sirtuin deacetylase assays 
 
In early sirtuin studies, different radioactive assays were used to determine the deacetylase 
activity of sirtuins. In these assays either, the acetyl group of the histone H4 lysine substrate is 
radiolabeled with 3H, or the nicotinamide group of NAD+ is labeled with 14C and the released 
14C-nicotinamide during the deacetylation reaction can be quantified (Kolle et al. 1998; Nare 
et al. 1999; Borra and Denu 2004; Borra et al. 2004). However, all these assays are time-
consuming and require the use of radioactivity. For this reason, several fluorescence-based 
assays were developed, where a fluorophore covalently conjugated to the substrate was 
detected (Hoffmann et al. 1999; Heltweg et al. 2003; Wegener et al. 2003). The fluorophores 
that were used and the quantification of deacetylated substrate differ, and not all of these 
assays are suitable for high-throughput analysis.  
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The most popular high-throughput fluorescence assay is the ‘Fluor the Lys’ assay (available 
from Biomol), whose substrate is based on an acetylated p53 peptide conjugated with a 
coumarin derivative (Marcotte et al. 2004). However, this assay is controversial, and data 
from several groups indicate that it leads to false positive results because of the fluorophore 
on the substrate. They showed increased fluorescence readings without truly increasing SirT1 
activity. Kaeberlein et al. utilized radioactivity deacetylase assays to evaluate the properties of 
the potential sirtuin activator resveratrol. For this purpose, a p53 peptide or an H4 peptide was 
used as a substrate, either containing or lacking the fluorophore. In both assays, resveratrol 
induced an enhancement of deacetylation only for substrates containing the fluorophore. 
Furthermore, it was shown that the presence of the fluorophore on the acetyl-peptide substrate 
decreases the binding affinity of SirT1 for this peptide. This indicates that resveratrol may 
stimulate deacetylation of substrates containing the fluorophore by increasing their binding 
affinity for SirT1 (Kaeberlein et al. 2005).  
To directly monitor SirT1 deacetylase activity without any interference or radioactivity, Beher 
et al. utilized a further deacetylase assay. It is an analytical method using high performance 
liquid chromatography (HPLC) to directly quantify products from the deacetylation reaction 
of SirT1 by their different retention times on the HPLC column (Hoffmann et al. 1999; Liu et 
al. 2008). In this study, it was shown that the ‘Fluor de Lys-SirT1’ substrate (RHKK(Ac)) 
without the fluorophore could not function as a SirT1 substrate. In this case, it seems that the 
fluorophore increases the binding affinity of SirT1 for the ‘Fluor de Lys-SirT1’ peptide, but it 
was proposed that this peptide is not an appropriate SirT1 substrate. Consistent with the 
results of (Kaeberlein et al. 2005), it has been shown that resveratrol does not activate SirT1 
when a substrate without a fluorophore is used (Beher et al. 2009). 
 
1.6 Sirtuin modulators 
 
Based on the variety of substrates of each sirtuin and associated functions in diverse pathways 
and tissues, sirtuins are enzymes that may have a significant influence on different human 
diseases. Therefore, small molecules that selectively influence the ability of sirtuins to 
deacetylate proteins may be useful therapeutic agents against a variety of human diseases. 
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1.6.1 Endogenous Modulators 
 
To date, two specific endogenous modulators of SirT1 have been identified. It was shown that 
the active regulator of SirT1 (AROS) interacts with and activates SirT1 (Kim et al. 2007b). 
AROS is a short nuclear protein of 142 amino acids that interacts with the N-terminus of 
SirT1 (114-217) both in vitro and in vivo. The AROS/SirT1 interaction promotes p53 
deacetylation and suppresses p53 transcriptional activity, thus mediating cell survival in 
response to DNA damage. It is not clear whether AROS induces a conformational change in 
SirT1 or whether AROS binds other proteins that regulate SirT1 activity. Further experiments 
are needed to determine the mechanism of AROS-mediated SirT1 activation.  
Another endogenous inhibitor of SirT1 is the human protein deleted in breast cancer 1 
(DBC1). It was previously identified as a region that is homozygously deleted in human 
breast cancer (Hamaguchi et al. 2002). Knockdown of DBC1 shows activation of SirT1 and a 
decrease of apoptosis by p53 through DNA-damaging agents (Kim et al. 2008; Zhao et al. 
2008). DBC1 binds directly through a leucine-zipper-like motif to the catalytic core domain 
of SirT1. It was shown that DBC1 contains an inactive Nudix domain (Anantharaman and 
Aravind 2008), which is able to bind NAD+-like molecules and the product of sirtuin 
deacetylation, OAADPr (Grubisha et al. 2006). Recently, Zannini et al. have shown that 
DBC1 is directly phosphorylated on Thr454 by ATM (ataxia telangiectasia mutated) and ATR 
(ataxia telangiectasia and Rad3 related) kinases. In response to DNA damage, ATM/ATR 
phosphorylate DBC1, and this enhances the DBC1-SirT1 interaction and thereby inhibits 
deacetylation of p53 and promotes apoptosis (Zannini et al. 2012). 
 
1.6.2 Small-molecule activators of sirtuins 
 
Because of the potential of sirtuins to influence a broad range of diseases including obesity, 
diabetes, cardiovascular, neuronal and aging-related diseases, the manipulation of sirtuin 
activity has obtained particular attention. CR is particularly beneficial in age-related disorders 
such as diabetes, cancer and cardiovascular disease, and it increases lifespan in animal models 
(Schwer and Verdin 2008). CR can also protect neurons against degeneration in animal 
models of Alzheimer’s disease (AD), Parkinson’s disease, Huntington’s disease (HD) and 
stroke (Mattson et al. 2003). Several lines of evidence suggest that the mechanisms of CR are 
mediated by sirtuins in yeast, worms, flies and mammals (Kaeberlein et al. 1999; Lin et al. 
2000; Tissenbaum and Guarente 2001; Wood et al. 2004; Boily et al. 2008). However, several 
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studies discovered that lifespan extension by CR is independent of sirtuins both in yeast and 
worms (Kaeberlein et al. 2004; Lamming et al. 2005; Tsuchiya et al. 2006; Greer et al. 2007). 
Nonetheless, it has been shown that the increase of sirtuin activities in mammals accelerates 
fat mobilization, glucose consumption and insulin sensibility. Therefore, there is growing 
interest in identifying molecules that activate sirtuin activity and mimic the effects of CR 
(Alcain and Villalba 2009a).  
A leading candidate for activating sirtuins is resveratrol, a polyphenol found in red wine. It 
was the first candidate to be reported to mimic CR by stimulating sirtuins (Howitz et al. 2003; 
Wood et al. 2004). It was identified in the ‘Fluor de Lys’ assay, together with other 
compounds that share structural similarity, for instance the chalcone butein and the flavone 
quercetin, as an activator of sirtuins (Howitz et al. 2003) (Figure 1.4). 
 
Figure 1.4: Chemical structure of sirtuin activators 
 
In the ‘Fluor de Lys’ assay, these compounds activated human SirT1 activity 4 to 13 fold. 
However, due to the problem with this ‘Fluor de Lys’ assay (described in 1.5), these 
activators might be experimental artifacts. Even so, it is thought that these compounds may 
activate sirtuin deacetylase activity in vivo. Resveratrol increases cell survival by stimulating 
SirT1-dependent p53 deacetylation. In yeast, it promotes rDNA stability and induces lifespan 
extension (Howitz et al. 2003). In D. melanogaster, a lifespan extension was observed when 
flies were fed an abundant diet containing fisetin or resveratrol (Wood et al. 2004). However, 
recently it has been shown that the effect of lifespan extension by resveratrol depends on both 
gender and dietary nutrient conditions in flies (Wang et al. 2011). In addition, Keaberlein et 
al. were unable to detect any significant increase of lifespan extension of several yeast strains 
in response to resveratrol (Kaeberlein et al. 2005). Nonetheless, it has been shown that 
resveratrol leads to increased survival and insulin sensitivity of mice that were fed a high-fat 
diet (Baur et al. 2006; Lagouge et al. 2006). Furthermore, resveratrol has also been reported to 
have a protective effect on vascular oxidative stress and inflammation, which can be induced 
by cigarette smoke. These protective effects were abolished by knockdown of SirT1, whereas 
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the overexpression of SirT1 mimicked the effect of resveratrol (Csiszar et al. 2008). However, 
the half-life of resveratrol in plasma is very short and it has a poor bioavailability (Asensi et 
al. 2002). The highest concentrations detected in rat tissues were found in liver and kidney 
and reached less than 1 % of the administered dose (El Mohsen et al. 2006). Therefore, Sirtris 
(a pharmaceutical company) has developed the SirT1 activator SRT501, a formulation of 
resveratrol that has an improved bioavailability of 11 % (Milne et al. 2007) and is being used 
in clinical trials. 
Researchers from Sirtris have identified further SirT1 activators by using the ‘Fluor the Lys’ 
assay. These compounds (Figure 1.5) are structural unrelated to resveratrol and 1000 - fold 
more potent than resveratrol (Milne et al. 2007). However, similar to resveratrol, there are 
also some controversies concerning their potential to activate SirT1 (Pacholec et al. 2010). 
Even so, they have been proposed for the treatment and/or prevention of a wide variety of 
diseases including diabetes, cancer, inflammation and many more. SRT1720, the most potent 
activator, has a bioavailability of 50 % and improves blood glucose level and insulin 
sensitivity by increased mitochondrial activity in diet-induced obese and genetically obese 
mice. SRT1460 and SRT2183 show similar effects, but to a lesser extent (Milne et al. 2007). 
They are already being used in clinical trials, but no further results have yet been published 
(Sirtris pharmaceuticals US2007037827; 2007).  
 
Figure 1.5: Chemical structures of SirT1 activators 
 
1.6.3 Small-molecule inhibitors of sirtuins 
 
Cancer cell lines, as well as tissue samples obtained from cancer patients, revealed higher 
endogenous levels of SirT1 expression compared to normal cells. As mentioned above, SirT1 
deacetylates and inhibits the tumour suppressor p53, resulting in reduced apoptosis in 
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response to DNA damaging agents. This raises the possibility that inhibiting SirT1 activity 
might suppress cancer cell proliferation, and that sirtuin inhibitors may be useful agents for 
cancer therapy.  
 
Splitomicin and its derivates 
Splitomicin was the first small-molecule sirtuin inhibitor to be identified. It was isolated in a 
high-throughput yeast phenotypic screen for inhibitors of Sir2 (Bedalov et al. 2001). It 
selectively inhibits yeast Sir2 and is an inefficient inhibitor for human sirtuins. In an in vitro 
histone deacetylase assay with a [3H]-acetylated histone H4 peptide, splitomicin inhibits yeast 
Sir2 with an IC50 value of 60 µM (Bedalov et al. 2001). However, it undergoes rapid 
hydrolysis at neutral pH, thus limiting its use in cell culture conditions. Several structure-
activity relationship studies have been performed and proposed that the hydrolytically instable 
aromatic lactone is required for the inhibition of Sir2 (Hirao et al. 2003; Posakony et al. 
2004). Based on these results, Pagans et al. identified the stable splitomicin derivate HR73 
(Figure 1.6), which inhibits human SirT1 activity in vitro with an IC50 value lower than 
5 µM. They could also show that HR73 in vivo suppresses Tat-dependent HIV1 (human 
immunodeficiency virus 1) transcription in a dose-dependent manner. Furthermore, it induces 
hyperacetylation of the tumour suppressor p53, a target of SirT1, at a concentration of 1 µM 
(Pagans et al. 2005).  
 
Figure 1.6: Structure of splitomicin and its analogue HR73 
 
The group of M. Jung (University of Freiburg) developed a series of analogues of 
β-phenylsplitomicins and found that the orientation of the β-phenyl group was important for 
the inhibition of SirT2. The most potent inhibitors of this series (5c and 8c; Figure 1.7) 
inhibit SirT2 with an IC50 value of 1.5 µM using a fluorescent lysine derivate (ZMAL) as a 
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substrate. Selected inhibitors of this series show antiproliferative properties and tubulin 
hyperacetylation in MCF7 breast cancer cells (Neugebauer et al. 2008).  
 
Figure 1.7: Structure of splitomicin derivates 
Both compounds 5c (β-phenyl-8-bromosplitomicin) and 8c (β-phenyl-8-methylsplitomicin) are analogues of 
splitomicin and selectively inhibit human SirT2 with an IC50 value of 1.5 µM (Neugebauer et al. 2008). 
 
Sirtinol and its derivates 
Besides splitomicin, sirtinol was also an early sirtuin inhibitor that was identified in a high 
throughput yeast phenotypic screen (Grozinger et al. 2001). Sirtinol inhibits yeast Sir2 in vitro 
(IC50 = 70 µM) as well as human SirT2 (IC50 = 40 µM), and therefore is potentially more 
potent against human SirT2. However, in vivo it affects only yeast Sir2 in a URA3 reporter 
gene assay. 25 µM of sirtinol inhibits transcriptional silencing at all three loci (HM, telomeric 
and rDNA) in yeast. In contrast, the sirtinol treatment of HeLa cells does not show an 
increased acetylation of α-tubulin or H3 and H4 acetylation, as is the case after TSA 
treatment. Further structure-activity studies were performed and suggest that the 2-hydroxyl-
1-naphtol moiety is sufficient for the inhibition of sirtuins (Grozinger et al. 2001). Mai et al. 
synthesized two further analogues of sirtinol, meta- and para-sirtinol (Figure 1.8), which are 
2- to 10-fold more potent than sirtinol against SirT1 and SirT2. In the yeast in vivo assay, the 
inhibitory effect is equal to sirtinol (Mai et al. 2005).  
 
Figure 1.8: Structure of sirtinol and its derivates 
Introduction 
 25 
Furthermore, sirtinol induces senescence-like growth arrest in human breast cancer MCF7 and 
lung cancer H1299 cells, which is accompanied by impaired activation of mitogen-activated 
protein kinase (MAPK) pathways (Ota et al. 2006). Treatment of the human prostate cancer 
cell line PC3 with sirtinol inhibits cell growth and increases sensitivity to two well-known 
anticancer drugs, cisplatin and camptothecin (Kojima et al. 2008). However, the molecular 
mechanism of theses effects is still unclear. These results suggest that inhibitors such as 
sirtinol might have high anticancer potential. A further sirtinol derivate, salermide, with a 
modified structure was synthesized to generate a stronger sirtuin inhibitor. The hydrophobic 
π−π interactions between amino acids F119 and H187 of SirT2 and the naphtol residue are 
maintained. Further, the change of the amide moiety created an additional polar interaction 
between the oxygen of the amide and the amino acid Q167 in the C-pocket of SirT2 (Q345 
correspondingly of SirT1) (Figure 1.9). The inhibitory effect was measured with the ‘Fluor 
de Lys’ assay, and it was shown that 100 µM of salermide inhibits 80 % of SirT1 activity, 
whereas the same concentration of sirtinol reduces SirT1 activity by < 5 %. However, 
salermide is more efficient at inhibiting SirT2; at 25 µM it inhibits 80 % of SirT2 activity 
(Lara et al. 2009).  
 
Figure 1.9: Schemes of proposed interactions for sirtinol and salermide with SirT2 
The blue arrows display the hydrophobic π−π interactions between amino acid F119 and H187 of SirT2 and the 
naphtol residue of both sirtinol and salermide. The red arrow shows the newly created polar interaction between 
the carbonyl group of salermide and amino acid Q167 of SirT2 (Lara et al. 2009). 
 
A range of in vivo experiments showed that salermide is well tolerated by mice at 
concentrations up to 100 µM and induces apoptosis in a wide range of cancer cell lines, but 
not in normal cells (Lara et al. 2009). Although salermide is a more potent SirT2 inhibitor, a 
putative SirT2-mediated apoptotic pathway was ruled out, because no alteration of the 
acetylation level of SirT2 targets, H4K16 or α-tubulin could be observed. Consistent with 
this, only knockdown of SirT1, but not SirT2, induces apoptosis in cancer cells. Finally, it 
was shown that the apoptotic effect of salermide is p53-independent. Salermide reactivates 
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proapoptotic genes such as PUMA, TNF and CASP8 that are epigenetically repressed 
exclusively in cancer cells by SirT1-mediated H4K16 deacetylation (Lara et al. 2009).  
 
Cambinol 
The group of Antonio Bedalov identified and characterized the compound cambinol (Heltweg 
et al. 2006), which shares a β-naphtol pharmacophore with sirtinol and splitomicin (Figure 
1.10). Cambinol inhibits human SirT1 and SirT2 deacetylase activity in vitro with IC50 values 
of 56 and 59 µM using a [3H]-acetylated histone H4 peptide as substrate. It also inhibits 
human SirT5 but to a lesser extent. In vivo experiments have shown that cambinol-induced 
inhibition of SirT1 sensitized cells to chemotherapeutic agents, such as etoposide and 
paclitaxel. Furthermore, it induces hyperacetylation of known sirtuin targets implicated in 
stress responses like p53, Ku70 and FOXO3a in combination with DNA damaging agents. An 
increase of acetylated α-tubulin could only be observed after treatment with cambinol in 
combination with TSA, which indicates a shared role of HDACs, especially HDAC6, and 
SirT2, in tubulin acetylation (Heltweg et al. 2006).  
 
Figure 1.10: Structure of cambinol 
 
Competition studies with NAD+ and peptide substrates show that cambinol competes with the 
peptide substrate-binding site and not with the NAD+-binding site, similar to splitomicin. This 
could be an explanation for the selectivity among Sir2 family members and low toxicity in 
vivo (Heltweg et al. 2006).  
 
Suramin 
A further potent sirtuin inhibitor is suramin (Figure 1.11), a symmetric polyanionic 
naphthylurea that was developed by Bayer AG in 1916. Originally, it was used for the 
treatment of trypanosomiasis, sleeping sickness, and onchocerciasis, also known as river 
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blindness. It inhibits sirtuins with IC50 values of 297 nM for SirT1, 1.15 µM for SirT2 and 
22 µM for SirT5 (Schuetz et al. 2007; Trapp et al. 2007).  
 
 
Figure 1.11: Structure of suramin 
 
It was reported that suramin has antitumor effects, and it also is a potent reverse transcriptase 
inhibitor (Perabo and Muller 2005). However, it is unsuitable for therapeutic treatment 
because of its neurotoxicity and other systemic side effects (Peltier and Russell 2002). Due to 
the highly polar sulfonic acids, its cellular uptake is generally quite limited. A low 
concentration of 2 % albumin in the medium inhibits suramin uptake by more than 90 % 
(Gagliardi et al. 1998). Structural studies with suramin and SirT5 showed that suramin targets 
the NAD+-binding pocket of SirT5. It thus seems to be nonselective for similar binding 
pockets (Schuetz et al. 2007). Indeed, suramin inhibits various other NAD+/NADP+-
dependent enzymes such as lactate dehydrogenase from Dirofilaria immitis and Onchocerca 
(Walter 1979; Walter and Schulz-Key 1980). 
 
Tenovin-1 and -6 
Lain et al. found two SirT1 inhibitors through a cell-based screen of 30.000 drug-like 
compounds with the ability to activate a p53-driven reporter gene. These two agents, tenovin-
1 and the more water-soluble tenovin-6 (Figure 1.12), decrease tumour growth in vitro in the 
one-digit micromolar range and delayed tumour growth in vivo as single agents (Lain et al. 
2008).  
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Figure 1.12: Structure of tenovin 
 
It has been shown that tenovin-6 inhibits the growth of S. cerevisiae cultures with an IC50 of 
30 µM and is more toxic to yeast than tenovin-1. Results of the yeast genetic screen showed 
that a strain heterozygous for a partial deletion of SIR2 is hypersensitive to tenovin-6. In the 
biochemical ‘Fluor de Lys’ assay, tenovin-6 decreases human SirT1 activity with an IC50 of 
21 µM and human SirT2 activity with an IC50 of 10 µM. It shows relatively poor inhibition of 
human SirT3 with an IC50 of 67 µM. In vivo, tenovin-1 and tenovin-6 increase levels of 
acetylated p53, H4K16 and α-tubulin (Lain et al. 2008).  
 
Indoles 
The most potent sirtuin inhibitors are a series of indoles that were found in the ‘Fluor de Lys’ 
assay against human SirT1. They are selective for SirT1 and inhibit it with IC50 values in the 
nanomolar range. The most potent inhibitor of this series is Ex527 (Figure 1.13), which has 
an IC50 value of 0.098 µM for SirT1, 19.6 µM for SirT2 and 48.7 µM for SirT3 (Napper et al. 
2005).  
 
Figure 1.13: Structure of the indole, Ex527 
 
Peck et al. have shown that Ex527 triggers cell cycle arrest but not cell death, as is the case 
for salermide and sirtinol. However, it is not able to increase the acetylation level of p53 and 
α−tubulin. Computational modelling and docking studies showed that Ex527 only forms 
strong interactions with SirT1, but not with SirT2. This is in contrast to salermide and sirtinol, 
which interact with both SirT1 and SirT2 and are able to induce acetylation of p53 and cell 
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death. Therefore, the authors proposed that the inhibition of both SirT1 and SirT2 is required 
for increased p53 acetylation and inducing cell death (Peck et al. 2010).  
 
1.7 Sirtuins and disease 
 
As mentioned above, several lines of investigation indicate that sirtuins are involved in the 
development of age-related diseases such as diabetes, cancer, neurodegenerative diseases and 
many more. The intriguing thing about sirtuins, especially of SirT1, is that both inhibiting and 
activating of its activity may be useful in therapies for a broad range of different diseases. 
SirT1 plays a dual role in cell survival and in cell death, depending on tissue and 
environmental cues and can be modulated in different directions by a variety of different 
stimuli. This paragraph concentrates on three examples of disorder, metabolic disease, cancer 
and neurodegenerative diseases. In the case of metabolic diseases such as diabetes or obesity, 
sirtuin activators are of interest, whereas sirtuin inhibitors may be useful agents for certain 
cancer therapies.  
 
Aging and metabolism 
Several studies have shown that a diet of reduced calories, also known as calorie restriction 
(CR), promotes lifespan extension by up to 50 % in many organisms, including yeast, worms, 
flies and mice (Sinclair 2005). In mammals, CR triggers physiological changes that improve 
glucose homeostasis. It decreases insulin and glucose levels and improves insulin sensitivity. 
It is thought to be relevant to aging, because decreasing insulin signaling is implicating in 
longevity regulation in studies of model organisms (Guarente and Kenyon 2000). During 
aging, signs of metabolic imbalance, such as insulin resistance, are observed with increasing 
frequency. Such abnormal metabolic processes often become manifest as obesity and diabetes 
(Haigis and Sinclair 2010). As mentioned above, several studies have shown that yeast Sir2 
and mammalian SirT1 may mediate the effects of CR, and although called to question, they 
were thought to be the missing link between genetic and environmental determinants of 
longevity (Guarente and Picard 2005). SirT1 interacts and deacetylates PGC-1α, a potent 
inducer of mitochondrial biogenesis as well as of the uptake and utilization of substrates for 
energy production in a number of cell types. Through deacetylation by SirT1, PGC-1α 
becomes active and promotes the induction of gluconeogenic genes and the suppression of 
glycolytic genes (Rodgers et al. 2005). In skeletal muscle, deacetylated and active PGC-1α 
promotes transcription of mitochondrial fatty acid oxidation genes, and SirT1 is required for 
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the switch to fatty acid oxidation under low nutrition conditions (Canto and Auwerx 2008; 
Canto and Auwerx 2009). SirT1 overexpressing transgenic mice gain weight, similar to wild 
type mice, but display protection from hepatic steatosis when fed a high-fat diet (Pfluger et al. 
2008). However, the connection between SirT1 and CR mediated longevity is still a matter of 
debate and therefore more in vivo studies are needed to understand these complex 
mechanisms. Based on the theory that increased SirT1 activity mimics the effects of CR, 
sirtuin activators could be useful agents for therapies against age-related diseases such as 
diabetes or obesity. 
 
Cancer 
In view of one well-known substrate of SirT1, the tumour suppressor p53, most of the 
evidence is in favour of SirT1 being an oncogene. Through deacetylation of lysine 382 on 
p53, SirT1 reduces p53 activation and prevents apoptosis and senescence in response to stress 
and DNA damage (Luo et al. 2001; Vaziri et al. 2001). As mentioned above, several cancer 
cell types including colon, skin, breast, prostate and lung cancers show higher expression of 
SirT1 compared to the corresponding normal tissue (Fraga and Esteller 2007; Stunkel et al. 
2007). Cancer cells with increased SirT1 levels have lower levels of acetylated p53, and they 
are more resistant to p53-dependent cell-cycle arrest and apoptosis (Luo et al. 2001; Vaziri et 
al. 2001). Consistent with this, cells derived from SIRT1 knockout mice or transfected with 
siRNA against SirT1 show increase levels of acetylated p53 and increase sensitivity to stress 
(Cheng et al. 2003; Ford et al. 2005; Lain et al. 2008). Furthermore, Ford et al. have shown 
that specific inhibition of SirT1 by siRNA can increase tumour cell death with no toxic effect 
on normal cells. However, in a subsequent study, it was shown that p53 is not essential for 
tumour cell death by SirT1, but this does not rule out participation by p53 (Ford et al. 2005). 
These results show that sirtuin inhibitors might be useful agents against cancer types that 
overexpress SirT1.  
However, the involvement of SirT1 in cancer biology is not simple. There also exist cancer 
cell types that show reduced levels of SirT1 compared to normal tissues, for example prostate 
and bladder carcinoma, glioblastoma and ovarian cancer (Wang et al. 2008). Several studies 
indicate that SirT1 can also act as a tumour suppressor. Firstly, SirT1 knockdown does not 
always affect cell viability or cell growth and is not always sufficient to induce activation of 
endogenous p53 (Ford et al. 2005; Solomon et al. 2006; Huang et al. 2008). Secondly, cell 
culture studies showed that SirT1 can also stimulate TNFα-induced cell death (Yeung et al. 
2004). In support of a tumour-suppressor function, SirT1 was shown to be involved in 
repairing broken DNA and maintaining genome stability (Oberdoerffer et al. 2008; Wang et 
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al. 2008). In the case of SirT1’s function as a tumour suppressor, small molecule activators 
may be useful therapeutic agents.  
 
Neurodegenerative diseases 
Several studies support the idea that sirtuins also have a therapeutic potential in 
neurodegenerative diseases such as stroke, Alzheimer’s disease (AD), Parkinson’s disease 
(PD) and Huntington’s disease.  
One hallmark of AD neuropathology is the abnormal deposition of the amyloid beta (Aβ) 
peptides in discrete area of the brain. Recent studies suggest that humans who maintain a low-
calorie diet have a reduced risk of developing AD (Hendrie et al. 2001; Luchsinger et al. 
2002; Mattson 2003). Furthermore, in various animal models, it has been shown that CR 
prevents amyloid neuropathology as seen in AD (Patel et al. 2005; Wang et al. 2005). Based 
on the evidence that sirtuins mediate the effect of CR, sirtuin activators may have beneficial 
effects in AD neuropathology. Consistent with this theory, SirT1 was shown to protect against 
neurodegeneration by deacetylation of p53 and PGC-1α in an AD mouse model (Kim et al. 
2007a). Furthermore, it has been shown that SirT1 protects against Aβ-induced neurotoxicity 
by inhibiting NF-κB signalling (Chen et al. 2005). 
After AD, PD is the second most common neurodegenerative disorder, which is characterized 
by the dysfunction and degeneration of dopaminergic neurons in the substantia nigra located 
in the midbrain. It alters the balance of neurotransmitters and results in the progressive loss of 
movement control (Gelb et al. 1999). The pathological hallmark of PD is the accumulation of 
protein aggregates called Lewy bodies (LB), which consist mainly of the protein α-synuclein 
(Spillantini et al. 1997). It was shown that SirT2 regulates α-synuclein inclusion number, size 
and cytotoxicity. Therefore, SirT2 inhibition prevents α-synuclein toxicity and salvages the 
degeneration of dopaminergic neurons in models of PD (Outeiro et al. 2007). However, it has 
also been shown that resveratrol protects SirT1-dependent neuroblastoma cells (SK-N-BE) 
against α-synuclein toxicity (Albani et al. 2009). The exact mechanism is still unknown, but 
these examples indicate that both sirtuin inhibitors and activators may be useful agents in 
neurodegenerative disorders, and that further investigation of the role of sirtuins in 
neuropathology is required.  
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1.8 Aim of this thesis 
 
Based on the fact that sirtuins can be found at different locations in the cell and have a variety 
of different substrates, they are involved in many biological processes. For this reason, they 
play important roles in several human diseases, including cancer, age-related diseases, type II 
diabetes and neurodegenerative diseases (Longo and Kennedy 2006; Milne and Denu 2008; 
Haigis and Sinclair 2010). Furthermore, SirT1 plays a dual role in cell survival and in cell 
death and it can be modulated in different directions by a variety of different stimuli. Several 
lines of investigation indicate that small molecules that inhibit or activate sirtuin activity are 
promising candidates for the therapy of a number of age-related diseases as well as cancer. 
Most of the known sirtuin modulators have high IC50 values, interact with multiple targets or 
have low bioavailability, therefore the identification of novel sirtuin modulators, especially of 
SirT1, is a promising field. For this reason, the aim of this thesis was the identification of 
novel sirtuin inhibitors and activators. For this approach we established a fluorescence-based 
MAL (Methylaminocoumarinacetyllysin) deacetylation assay that is suitable for a high-
throughput screen (Hoffmann et al. 1999; Heltweg and Jung 2003). Subsequently, two 
libraries (BIOMOL, ChemBioNet) were screened in order to identify new inhibitors as well as 
activators of SirT1. Furthermore, the results of the screens were validated with the help of 
another deacetylase activity assay that is based on an acetylated p53-derived peptide without 
fluorophore. Moreover, the specificity of the identified modulators was characterized by the 
usage of other sirtuin family members in the MAL deacetylation assay. Furthermore, we 
measured the inhibitory effect of the identified compounds on SirT1 constructs that were 
truncated in the N-terminal region in order to determine potential interaction sites between the 
inhibitor and SirT1. In a second set of experiments, the in vivo influence of the inhibitors and 
their anticancer potential were analyzed. Furthermore, we determined whether the inhibitors 
might affect acetylation of known in vivo targets of sirtuins, such as p53 and α-tubulin.  
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2. Material & Methods 
2.1 Media and growth conditions 
 
E. coli strains used for plasmid amplification were cultured according to standard procedures 
(Sambrook 1989) at 37 °C in Luria-Bertani medium (LB: 5 g/l yeast extract, 10 g/l tryptone, 
5 g/l NaCl) supplemented with either 100 µg/ml ampicillin or 50 µg/ml kanamycin. In the 
case of the Rosetta E. coli strain 34 µg/ml chloramphenicol was additionally added. 
S. cerevisiae were cultured at 30 °C in standard complete medium (YPD: 10 g/l yeast extract, 
20 g/l peptone, 2 g/l glucose) or standard minimal medium (YM: 6,7 g/l yeast nitrogen base 
w/o amino acids) as described previously (Sherman, 1991). YM medium was supplemented 
with 2 % glucose and as required with 20 µg/ml for adenine, uracil, tryptophan, methionine 
and histidine or 30 µg/ml for leucine and lysine. YM + 5-FOA (5-fluoro-orotic acid; US 
Biological) medium contained 5-FOA at 1 mg/ml, 20 µg/ml uracil and 2 % glucose.  
Human cancer cell lines were cultured in RPMI 1640 medium (Biochrom) containing 10 % or 
0.5 % fetal calf serum (FCS), 1 % penicillin/streptomycin and 2 mM L-glutamine. Cells were 
maintained at 37 °C in a humidified atmosphere containing 5 % CO2. Cells were passaged at 
70-80 % confluence by trypsinization. 
 
2.2 E. coli strains 
 
All E. coli strains used in this study were from the laboratory strain collection.  
 
Tabelle 2.1: E. coli strains used in this study 
Strain Genotype 
DH5α
 F
-
 ϕ80dlacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, mk+) phoA supE44 
thi-1 gyrA96 relA1 λ
-
 (Invitrogen) 
Rosetta (DE3)
 
F
-
 ompT hsdSB (rB- mB-) gal dcm pRARE (CamR) (Merck) 
 
2.3 Saccharomyces cerevisiae strains  
 
Yeast strains used in this study are listed in Table 2.2 Unless indicated otherwise, strains 
were constructed during this study or were from the laboratory strain collection. Yeast was 
grown and manipulated according to standard procedures (Sherman, 1991). Marker selection 
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was performed on selective YM plates. Plates containing 5-FOA were used to select against 
URA3.  
 
Tabelle 2.2: S. cerevisiae strains used in this study 
Strain Genotype 
AEY264 MATa his4 
AEY325 ROY1 mataΔp hmlαΔp HMRssα trp1-1 ade2 leu2-3,112 ura3, his- 
AEY4017 MATα ade2-1 ura3-1 his3-11,15 leu2-3, 112 trp1-1 can1-100 (=W303-1B) adh4::URA3-UASGal-(C1-3A)n sir2Δ::KanMX 
AEY4335 AEY4017 + pAE1369 
AEY4336 AEY4017 + pAE1365 
AEY4337 AEY4017 + pAE1366 
AEY4338 AEY4017 + pAE1370 
AEY4339 AEY4017 + pAE1367 
AEY4340 AEY4017 + pAE1368 
 
2.4 Human cancer cell lines  
 
Cell lines used in this study were obtained from M. Schuler (University Hospital Essen).  
A549 cell line was initiated in 1972 by D.J. Giard et al. through explant culture of lung 
carcinomatous tissue from a 58 year old Caucasian male (www.atcc.org). 
NCI-H460 cell line was derived by A.F. Gazdar and associates in 1982 from the pleural fluid 
of a patient with large cell cancer of the lung. The cells express detectable p53 mRNA levels 
comparable to normal lung tissues and exhibit no gross structural DNA abnormalities 
(www.atcc.org).  
NCI-H1299 cell line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from 
a lymph node metastasis. The cells have a homozygous partial deletion of the p53 gene and 
lack expression of p53 protein (www.atcc.org). 
 
2.5 Molecular cloning 
 
Plasmid generation was performed according to standard cloning techniques (Sambrook et al. 
1989). Kits for plasmid isolation and gel elution were purchased from Qiagen and Macherey-
Nagel. Restriction enzymes and respective buffers were used from NEB, pGEMT vector 
systems kit from Promega and T4 DNA Ligase from Roche.  
In yeast, gene fusions were created by PCR-mediated plasmid gap repair (P-MPGR). For this 
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purpose, the corresponding DNA fragments were amplified by PCR and introduced into a 
linearized plasmid by homologous recombination in yeast. 
For amplification of truncated SIRT1 constructs for heterologous expression, the SIRT1 full-
length plasmid (pAE1287) was used as template. One specific reverse primer with overhang 
containing a BamHI restriction site and different specific forward primers with overhang 
containing an NdeI restriction site were used to amplify SIRT1. These truncations were 
cloned into the pET15b vector. For the exchange of single amino acids within the SIRT1 
catalytic domain to create inactive mutants, the PCR sewing technique was used. In the first 
step, short complementary overhangs were generated that contain the desired mutations and 
served as polymerase start site in a second PCR reaction. 
 
Tabelle 2.3: Plasmids used in this study 
Plasmida Description  Source 
pAE231 pRS315-Sir2  
pAE232 pRS315-Sir3  
pAE1287 pET30z-SIRT1   
pAE1365 pRS414-Sir3-Sir2 (243-562) Marc R. Gartenberg 
pAE1366 pRS414-Sir3-Hos3 (2-549) Marc R. Gartenberg 
pAE1367 pRS414-LexA-Sir2 (78-252)-Hos3 (2-549)-Sir2 (522-562) Marc R. Gartenberg 
pAE1368 pRS414-LexA-Sir2 (78-252)-Hos3 (2-549 AA)-Sir2 (522-562) Marc R. Gartenberg 
pAE1369 pRS414-Sir3-Sir2 (2-562) Marc R. Gartenberg 
pAE1370 pRS414-LexA-Sir2 (78-562) Marc R. Gartenberg 
pAE1423 pET30z-SIRT1 (Rosetta)  
pAE1394 pET24a(+)-Sir2-His6x (Rosetta)  
pAE1690 pET15b-SIRT1_A (156-664)  
pAE1692 pET15b-SIRT1_B (172-664)  
pAE1694 pET15b-SIRT1_C (219-664)  
pAE1696 pET15b-SIRT1_D (225-664)  
pAE1698 pET15b-SIRT1_E (230-664)  
pAE1700 pET15b-SIRT1_F (235-664)  
pAE1702 pET15b-SIRT1_G (240-664)  
pAE1704 pET30z-SIRT1_N (N346A)  
pAE1706 pET30z-SIRT1_H (H363A)  
a Unless indicated otherwise, plasmids were constructed during the course of this study or were from the 
laboratory plasmid collection. 
 
Oligonucleotides used for plasmid constructions are listed in Table 2.4. Oligonucleotides 
were designed using Ape software and synthesized by Metabion.  
 
 
Material & Methods 
 36 
Tabelle 2.4: Oligonucleotides used for cloning and mutagenesis 
Oligonucleotides Sequence (in 5’ to 3’ direction)a 
SIRT1 fw CAGCcatatgATGGCGGACGAGGCG 
SIRT1 rv TATAggatccTTAGTCATCTTCAGAGTCTGAATATACCTC 
SIRT1_A fw CAGCcatatgATGGGTTTTCATTCCTGTGAAAGTGATGAGGAG 
SIRT1_B fw CAGCcatatgATGAGCTCTAGTGACTGGACTCCAAGGCCACGG 
SIRT1_C fw CAGCcatatgATGACACTGTGGCAGATTGTTATTAATATCCTT 
SIRT1_D fw CAGCcatatgATGATTAATATCCTTTCAGAACCACCAAAAAGG 
SIRT1_E fw CAGCcatatgATGGAACCACCAAAAAGGAAAAAAAGAAAAGAT 
SIRT1_F fw CAGCcatatgATGAAAAAAAGAAAAGATATTAATACAATTGAAGATGCT 
SIRT1_G fw CAGCcatatgATGATTAATACAATTGAAGATGCTGTGAAATTACT 
N346A rv CCTGTTCCAGCGTGTCTATGGCCTGGGTATAGTTGCGAAGTAGTT 
H363A rv GATGCTGTTGCAAAGGAACCAGCACACTGAATTATCCTTTGGATTCCC 
a Sites for restriction endonucleases are shown in lower case letters, bold letters indicate nucleotide changes as 
compared to wild-type SirT1. 
 
2.6 Silencing assays in Saccharomyces cerevisiae 
 
HM silencing was measured by determining the mating ability of a strain with a mating-type 
tester strain in a patch-mating assay. For this assay, the candidate strains were streaked in 
1 cm2 patches on YPD plates and grown over night at 30 °C. Thereafter, they were replicated 
on YM plates with a lawn of 2 OD600 of a mating-type tester strain MATa his4 (AEY264) and 
incubated for two days at 30 °C. The amount of grown diploid cells served as a measurement 
of the mating efficiency and thus HMR silencing. To test the influence of compounds on HM 
silencing, the mating-type tester and ROYI (AEY325) strain were grown to 0.9 OD600, mixed 
and plated together on a YM plate to a final OD600 of 0.5 of each strain. Subsequently, filters 
containing different amounts of compound solution (in DMSO) were placed on this YM plate. 
Cells were incubated for two days at 30 °C. The yield of diploid cells was taken as indicator 
for HM silencing.  
Telomeric silencing assays were performed using a telomeric URA3 reporter (Gottschling et 
al. 1990). URA3 silencing was tested by spotting serial dilutions of cells on YM plates with or 
without uracil and YM plates with 5-FOA. After incubation of two days at 30 °C, the growth 
of the cells was monitored.  
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2.7 Protein purification of recombinant SirT1 
 
Polyhistidine-tagged recombinant proteins can be purified with the help of immobilized metal 
affinity chromatography (IMAC (Hochuli 1988)), known as His-tag purification. This 
purification is based on the affinity of the 6xHis-Tag for Ni2+-ions, which are immobilized 
onto a chelating surface. It allows efficient purifications under native and denaturating 
conditions.  
Rosetta E. coli strains carrying the expression vector were freshly grown in LB medium 
supplemented with either 100 µg/ml ampicilin or 50 µg/ml kanamycin and 34 µg/ml 
chloramphenicol and used to inoculate a larger culture. Depending on the protein, 500 ml up 
to 2 l LB medium supplemented with either 100 µg/ml ampicilin or 50 µg/ml kanamycin and 
34 µg/ml chloramphenicol were inoculated to a final OD600 of 0.2. Cells were grown at 37 °C 
to an OD600 of 0.6-0.9, and protein expression was subsequently induced with 1 mM IPTG 
(Isopropyl-β-D-thiogalactopyranosid) for 4 h at 30 °C or 37 °C. Subsequently harvested at 
6000 rpm, 4 °C for 10 min, mixed with small amounts of lysozyme and stored at -20 °C. Cell 
pellets were slowly thawed in the fridge and lysed in sonication buffer (30 mM potassium 
phosphate buffer (KPi) pH 7.0, 300 mM KCl, 10 % Glycerin (v/v), 0.1 mM DTT, complete 
Protease Inhibitor Cocktail; Roche) by repeated addition of small amounts of lysozyme. This 
lysate was stirred on ice up to 2 h and sonicated for 10 min using 10 sec intervals. 
Subsequently, the lysate was centrifuged at 4000 rpm for 30 min until it was almost clear. The 
lysate was incubated with 1,5 ml Ni-beads (Profinity IMAC Ni-charged resin; Bio-Rad), 
which were equilibrated with sonication buffer containing 20 mM imidazole, at 4 °C over 
night and then loaded onto a column. The protein-Ni-beads mixture was washed twice with 
sonication buffer containing 20-50 mM imidazole, and the protein was eluted from the beads 
with elution buffer (30 mM KPi pH 7.0, 300 mM KCl, 10 % Glycerin (v/v) 0.1 mM DTT) 
containing increasing imidazole concentrations (90-250 mM). Elution fractions containing the 
protein of interest (as measured by SDS-PAGE) were collected and dialyzed at 4 °C in 
dialysis buffer I (30 mM KPi pH 7.0, 200 mM KCl, 20 % Glycerin (v/v), 0.1 mM EDTA, 
1 mM DTT) for 3 h and in dialysis buffer II (30 mM KPi pH 7.0, 100 mM KCl, 50 % 
Glycerin (v/v), 0.1 mM EDTA, 1 mM DTT) over night. The final protein concentration was 
determined by Bradford protein assay (Bio-Rad) according to the manufacturer’s instructions.  
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2.8 Protein extraction from human cells 
 
Cells cultured in 6-well plates (300000 cells per well) were collected in 2-ml tubes by 
trypsinization and centrifugation at 1400 rpm for 10 min. The pellet was washed with cold 
PBS (Phosphat buffered Saline) and lysed in 100 µl lysis buffer (20 mM Hepes pH 7.9, 
400 mM NaCl, 25 % Glycerin (v/v), 1 mM EDTA, 1 mM EGTA, 1 mM DTT, complete 
Protease Inhibitor Cocktail; Roche and 1 % NP-40) for at least 30 min on ice. Subsequently, 
the cell lysate was flash frozen in liquid nitrogen and thawed on ice. The samples were 
centrifuged at 13000 rpm, 4 °C for 20 min and the supernatant containing proteins was 
transferred into a fresh 1.5-ml tube. The final protein concentration was determined by 
Bradford protein assay (Bio-Rad) before the samples were stored at -80 °C until further use. 
 
2.9 Acid extraction of histones from human cells 
 
For histone extraction, cells cultured in a 100 mm dish (2*106 cells per dish) were collected in 
2-ml tubes by trypsinization and centrifugation at 1400 rpm for 10 min. The pellet was 
washed with 2 ml cold PBS and centrifuged again. The supernatant was discard and the pellet 
was re-suspended in 1 ml hypotonic lysis buffer (10 mM Tris-HCl pH 8.0, 1 mM KCl, 
1.5 mM MgCl2, 1 mM DTT, complete Protease Inhibitor Cocktail (Roche) and 1 mM PMSF 
(Phenylmethylsulfonylfluorid)) and incubated for at least 1 h on a rotator at 4 °C. The intact 
nuclei were collected by centrifugation at 13000 rpm, 4 °C for 20 min. The supernatant was 
discard again and the nuclei were re-suspended in 400 µl 0.2 M H2SO4 and incubated on the 
rotator at 4 °C over night. The samples were centrifuged at 13000 rpm, 4 °C for 20 min to 
remove nuclear debris. The supernatant containing histones was transferred to a fresh 1.5-ml 
tube, mixed gently with 132 µl TCA (Trichloroacetic acid) and incubated on ice for at least 
1 h. Histones were collected by centrifugation at 13000 rpm, 4 °C for 20 min and the 
supernatant was carefully removed. The histone pellet was washed twice with ice-cold 
acetone without dissolving the pellet. The histone pellet was then air-dried at room 
temperature and dissolved in 50 µl H2O. The histone concentration was determined by 
Bradford protein assay (Bio-Rad) before the samples were stored at -80 °C until further use. 
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2.10 SDS-PAGE and Western Blotting 
 
Proteins were separated by SDS-PAGE in Tris-glycine buffer according to standard procedure 
(Laemmli 1970). Gels were stained with Coomassie blue (Bio-Rad) according to the 
manufacturer’s instructions. Protein transfer to nitrocellulose membranes (Bio-Rad, GE 
Healthcare, Whatman) was accomplished by blotting with the Bio-Rad Tank Transfer System 
with 5.5 mA x h/cm2 in transfer buffer (48 mM Tris-base, 39 mM glycine, 0.037 % SDS, 
20 % methanol). The membrane was subsequently blocked for at least 1-2 h at room 
temperature in 5 % BSA, TBST (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 % Tween-20, 
5 % BSA powder) or in 3 % BA (ECL Advance blocking agent, GE Healthcare), 
TBS / 0.05 % Tween-20, depending on antibody used. Primary antibody was incubated over 
night at 4 °C and secondary antibody for 1 h at room temperature, both in 5 % BSA or 3 % 
BA (concentrations see Table below). Thereafter and between the antibodies the membrane 
was washed up to 5 times, in total no longer than 1 h in TBST. Western blot signals were 
detected using Amersham ECLTM Western Blotting Analysis System (GE Healthcare) and 
Amersham HyperfilmTM ECL chemiluminiscence films (GE Healthcare). 
 
Tabelle 2.5: Antibodies used in this study 
Antibody Company (Catalog) Application notes 
α-poly-Histidin Sigma 1:3000 in 5 % BSA 
α-Ac(K382)-p53 Millipore (04-1146) 1:1000 in 3 % BA 
α-p53 BD Pharmingen (554294) 1:1000 in 3 % BA 
α-Ac(K40)-Tubulin Santa Cruz (sc-23950) 1:1000 in 3 % BA 
α-Tubulin Abcam (ab15246) 1:1000 in 3 % BA 
α-rabbit-HRP Sigma (A0545) 1:5000 in same solution as primary antibody 
α-mouse-HRP Sigma (A9044) 1:1000 in same solution as primary antibody 
  
2.11 Fluorescence based deacetylase assay 
 
The fluorescence-based assay used here is a nonradioactive assay to measure deacetylase 
activity of proteins and is suitable for high throughput screening (Hoffmann et al. 1999; 
Wegener et al. 2003). It is based on a substrate that contains an ε-acetylated lysine residue 
followed by a 7-amino-4-methylcoumarin moiety at their carboxy terminus (MAL = 
Methylaminocoumarinacetyllysin; Bachem). The assay is a two-step reaction as shown in 
Figure 2.1. In the first reaction, the substrate MAL is deacetylated to ML (Methylamino-
cumarinlysin) by sirtuin. In the second reaction, ML is recognized as substrate by trypsin, 
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which cleaves only the deacetylated substrate ML. This generates the fluorophore AMC (7-
amino-4-methylcoumarin) that can be detected by a fluorometic reader. AMC fluoresces at a 
excitation wavelength of 390 nm and an emission wavelength of 460 nm. The amount of 
fluorescence produced is proportional to the amount of deacetylated substrate.  
 
Figure 2.1: Fluorescence-Assay to measure deacetylase activity of sirtuins 
In the first reaction the ε−acetylated lysine substrate MAL is deacetylated to ML by sirtuin. In the second 
reaction only the deacetylated substrate ML is cleaved by trypsin. This generates the fluorophore AMC, which 
can be detected by a fluorometic reader (390, 460 nm).  
 
Purified recombinant human SirT1 was diluted in 1x SirT buffer (25 mM Tris-HCl pH 8, 
1 mM MgCl2, 2,7 mM KCl, 137 mM NaCl, freshly added 1 mg/ml BSA and 1 mM DTT). 
10 µl of this dilution was placed per well in a 384-well Plate. Subsequently, 1 µl DMSO 
(positive and negative control reaction) or 1 µl compound (diluted in DMSO) was added in 
each well and incubated for 10 min at room temperature. The reaction was started with 10 µl 
substrate solution (100 µM MAL, 2 mM NAD+ in 1x SirT buffer) followed by 4 h of 
incubation at 37 °C. After this incubation time, 20 µl trypsin solution (0,5 mg/ml in 1x SIRT 
buffer) was added and incubated for 1 h at 37 °C. The fluorescence was measured at an 
excitation wavelength of 360 nm and an emission wavelength of 465 nm with the 
fluorescence reader (GENiosPro, Tecan). With all measurements, positive and negative 
control reactions were performed simultaneously. Negative control reactions contain only the 
substrate solution, DMSO and trypsin solution, but no enzyme to determine the background 
fluorescence and subtract it from the positive control and the other measured values.  
The control reaction to test for autofluorescence of each compound contains only the 
acetylated substrate (MAL) and the respective compound, but no enzyme. The control 
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reaction to test for trypsin inhibition contains the deacetylated substrate (ML; Bachem) and 
the trypsin solution and the compounds as applicable. 
 
2.12 High Performance Liquid Chromatography (HPLC)-based deacetylase 
assay 
 
The HPLC-based deacetylase assay was used to measured deacetylase activity of SirT1 
without using a fluorescence-labelled substrate (Liu et al. 2008). Purified recombinant human 
SirT1 diluted in 1x SirT buffer was incubated with 100 µM acetylated p53 peptide (Ac-p53, 
HLKSKKGQSTSRHKK(Ac)LMFK, Biosyntan), 1 mM NAD+ and 1 µl DMSO (positive 
control) or 1 µl compound (diluted in DMSO) for 30 min at 37 °C. Samples were analysed by 
HPLC (Jasco) using a Jupiter RP-C18 (5 micron, 250 mm x 4.60 mm; Phenomenex) column. 
A total injection volume of 40 µl of assay reaction was loaded on the column. The separation 
of Ac-p53 and deacetylated p53 peptide was achieved by a linear gradient of 1 % to 35 % 
acetonitrile in water containing 0.1 % TFA (Trifluoroacetic acid) over 30 min. The peptides 
were detected and quantified using a UV detector at a wavelength of 214 nm.  
 
2.13 Flow cytometry 
 
For cell cycle analysis of human cell culture, cells were cultured in 6-well plates (50000 cells 
per well) and incubated with compounds of interest for 24 h or 48 h at 37 °C. Subsequently, 
the supernatant and the cells were collected in 5-ml polypropylene tubes (BD). After 
centrifugation at 1400 rpm for 10 min, the supernatant was discarded and the cell pellet was 
dissolved in 300 µl propidium iodide staining solution (50 µg/ml propidium iodide, 0.1 % 
sodium citrate, 0.1 % Triton X-100). The specimens were incubated in the dark at 4 °C for at 
least 30 min and analysed with the flow cytometer (Calibur, BD).  
 
2.14 Cell Proliferation and Viability Assay (MTT assay) 
 
This assay is a sensitive, in vitro assay for the measurement of cell proliferation and reduction 
of cell viability, when metabolic events lead to apoptosis or necrosis.  
Cells were cultured in a flat-bottom, 96-well tissue plate (2000-3000 cells per well) and 
incubated with compounds of interest at 37 °C. After a define incubation time, cells were 
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treated with 10 µl/well of a tetrazolium compound MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide), which is reduced by metabolically active cells to insoluble 
purple formazan dye crystals, for 4 h at 37 °C. Through the addition of 100 µl/well 
solubilisation solution (0.01 M HCl, 10 % SDS) and incubation over night at 37 °C, the 
crystals were solubilised, and the absorbance was read using a spectrophotometer (550-
600 nm). The rate of MTT reduction is proportional to the rate of cell proliferation or cell 
viability.  
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3. Results 
 
3.1 Identification of novel sirtuin modulators 
3.1.1 Establishment of MAL deacetylation assay 
To date, several inhibitors and putative activators of sirtuins, especially of SirT1, are known 
(reviewed in (Alcain and Villalba 2009a; Alcain and Villalba 2009b)). However, most of 
them have a low bioavailability, a high IC50 value and interact with multiple targets. For this 
reason, we sought to identify new inhibitors and activators of sirtuins, with a focus on SirT1, 
in a high throughput screen. In the past, the deacetylation activity of sirtuins was measured in 
assays based on protein marked with radioactivity labeled acetyl-lysine residues, which 
however are not suitable for high-throughput screening. Subsequently, the fluorescence-based 
assay ‘Fluor de Lys’ was developed that functions without the use of radioactivity and is 
convenient for high-throughput screening (Heltweg et al. 2003; Wegener et al. 2003). As 
mentioned above, this assay is controversial, because of the fluorophore on the substrate that 
influences the activity of sirtuins. Nonetheless, we sought to establish this assay in our lab and 
use it to screen different compound libraries, because it is easy to perform, suitable for high-
throughput and cost-effective. However, we used a modified assay, because the ‘Fluor de 
Lys’ assay was only available as kit (BIOMOL) and cost-intensive. We used, instead of a 
p53-derived peptide, an acetylated lysine coupled with a fluorophore (MAL; (Hoffmann et al. 
1999)) that is commercially available. To set up the assay, different assay conditions such as 
substrate (MAL), NAD+ and sirtuin concentrations were assessed. Furthermore, different time 
course experiments were performed in order to determine the adequate incubation time of the 
deacetylation reaction as well as the subsequent trypsin cleavage reaction (described in 2.11). 
In view of the fact that we planned to perform high-throughput screens, the MAL 
deacetylation assay was adapted for 384-well low volume plates. In order to determine the 
appropriate 384-well plate, several plates (Corning, Eppendorf) with different properties such 
as low binding affinity and low background noise were tested. Subsequently, the complete 
reaction volume was reduced from 50 µM to 20 µM, whereas the substance concentrations 
were constant.  
As a source of SirT1, polyhistidin-tagged recombinant human SirT1 protein was expressed 
and purified from E. coli. The protein was eluted from the Ni2+-agarose beads with increasing 
imidazole concentrations and the elution fractions were subjected for SDS-PAGE gel 
electrophoresis. The fractions were analyzed by Western blotting against SirT1-6xHis with an 
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α-poly-His antibody, and the proteins were stained with Coomassie blue to determine which 
fractions contained most of the protein of interest. The corresponding fractions were pooled 
and dialyzed as described in 2.7. As shown in Figure 3.1, next to the SirT1 protein band, 
additional bands could be observed in the Coomassie blue stained SDS-PAGE gel, resulting 
probably from other contaminating proteins that were co-eluted from the column. The 
expected molecular weight of SirT1 was 81.7 kDa (Frye 2000), however it ran constantly 
below the 130 kDa band of the molecular weight marker.  
 
Figure 3.1: Purification of recombinant human SirT1 
Coomassie-stained SDS-PAGE gel of purified fraction of recombinant human SirT1, the respective band is 
highlighted by the arrow. SirT1-containing fraction was identified by Western blotting with α-poly-His 
antibody. 
 
The activity of the purified SirT1 was subsequently tested in the MAL deacetylation assay. 
For this purpose, a serial dilution of the purified SirT1 was performed, and 10 µl of each 
dilution was placed in wells of the 384-well plate. Subsequently, 1 µl of DMSO or a 
compound of interest was added and pre-incubated for 10 min at room temperature. The 
deacetylation reaction was initiated with the addition of 10 µl 2x concentrated substrate 
solution containing MAL (200 µM) and NAD+ (2 mM). After an incubation time of 4 h at 
37 °C, the reactions were stopped with the addition of 20 µl trypsin solution (0.5 mg/ml) and 
a further incubation of 1 h at 37 °C. Finally, the fluorescence was measured using a 
fluorescence reader (GENiosPro, TECAN) with the excitation wavelength set to 360 nm and 
the emission set to 465 nm.  
In the following experiments, a negative control reaction where the sirtuin is absent as well as 
a control reaction containing DMSO was performed simultaneously with test for inhibition or 
activation. The negative control was subtracted from each measurement value, and the DMSO 
control was set to 100 %. As shown in Figure 3.2, the purified SirT1 protein (approximately 
0.5 µM) was active, and it could be stimulated by resveratrol, the putative activator of SirT1 
and inhibited by suramin, the well-known inhibitor of SirT1. This indicated that the purified 
enzyme was indeed active and constituted SirT1.  
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Figure 3.2: Deacetylase activity of purified recombinant human SirT1 
The deacetylase activity of SirT1 purified from E. coli was measured by the MAL deacetylation assay and can be 
enhanced by the addition of 25 µM of resveratrol, a known activator of SirT1. Conversely 12.5 µM of suramin, a 
known inhibitor of SirT1, impairs the activity of SirT1. The control reaction containing DMSO was set to 
100 %. Values correspond to the average enzyme activity of three independent experiments ± standard deviation. 
 
To verify that the deacetylation activity that was measured in the MAL deacetylation assay, 
really depended on the purified SirT1 protein, we constructed two inactive SirT1 constructs. 
The activity of yeast Sir2 depends on amino acids N345 and H364, which are highly conserved 
residues in the catalytic core domain of sirtuins (Imai et al. 2000). Correspondingly, we 
generated alanine mutations of N346 (SirT1-N346A) and H363 (SirT1-H363A) of SirT1 
(pAE1706 and pAE1707) by site-directed mutagenesis. Similar to SirT1, both mutants were 
expressed and purified from E. coli using His-tag purification. The amount of protein was 
determined by a Bradford assay and Coomassie stained SDS-PAGE gel, and the SirT1 
corresponding fractions were also analyzed by Western blotting with α-poly-His antibody 
(Figure 3.3A).  
   
 
Figure 3.3: SirT1 catalytic mutants showed no deacetylation activity 
(A) The amount of protein was determined by Coomassie stained SDS-PAGE gel, the respective band is 
highlighted by the arrow. The expression of SirT1 protein in the respective fractions was analyzed by Western 
blotting with α-poly-His antibody. (B) Deacetylase activity of inactive SirT1 mutants (SirT1-N346A and SirT1-
H363A) was measured by the MAL deacetylation assay and compared with active SirT1 purification. From all 
SirT1 constructs the same amount of protein was put into the MAL deacetylation assay and their activity was 
measured. The values correspond to the average enzyme activity of a three-fold determination ± standard 
deviation of one experiment. 
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Subsequently, the activity of SirT1-N346A and SirT1-H363A was analyzed with the MAL 
deacetylation assay in comparison to a purification of the wild-type SirT1 protein. As can be 
seen in Figure 3.3B, both alanine mutants showed no deacetylase activity in comparison to 
wild type SirT1. This suggested that the observed deacetylase activity in the MAL 
deacetylation assay was indeed the activity of SirT1 rather than a co-purifying protein.  
 
3.1.2 High throughput screening of compound libraries 
 
BIOMOL library 
After the establishment of the MAL deacetylation assay, a small library of approximately 500 
natural compounds (purchased from BIOMOL) was screened for SirT1-deacetylating 
activities. All compounds were diluted in DMSO (1 mg/ml), and approximately 125 µM of 
each compound was added to the 384-well plate for the SirT1 deacetylation assay. This screen 
resulted in 13 potential activators and 15 potential inhibitors of SirT1, whereby compounds 
with an inhibition of more than 50 % (i.e. decreased fluorescence as compared to the control 
reaction) or an activation of more than 200 % of SirT1 activity (i.e. increased fluorescence 
compared to the control reaction) were considered.  
It was possible that some of the potential activators showed autofluorescence and thus 
increased fluorescence readings without truly increasing MAL deacetylation. To examine the 
fluorescence measurements, each compound was taken in a MAL reaction without the 
addition of SirT1. Indeed, 3 of these 13 activators showed increased fluorescence 
(Camptothecin, Harmaline HCl, Harmalol HCl), although no enzyme was added, indicating 
autofluorescence. These compounds therefore were not purchased. 
In the case of inhibitors, it was possible that they inhibited the trypsin reaction rather than 
MAL deacetylation, which would also lead to decreased fluorescence readings. To examine 
this, we obtained the deacetylated substrate (ML) and incubated it with trypsin in the presence 
of the inhibitor. If the inhibitors do not inhibit the trypsin reaction, then trypsin cleavage of 
ML showed and to a measurable increases fluorescence. This was the case for all 15 inhibitors 
indicating that they did not inhibit trypsin cleavage.  
In a next step, the remaining 10 activators and 15 inhibitors were validated in the MAL 
deacetylation assay. Different concentrations of each compound were measured for MAL 
deacetylation in at least three independent experiments. After the validation, only 3 activators 
and 4 inhibitors could be verified, because the other compounds showed no activation or 
inhibition in dose-dependent manner. Interestingly, three compounds, quercetin, luteolin and 
kaempferol, are already known as SirT1 activators (Howitz et al. 2003). One of the four 
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inhibitors was rottlerin, a known protein kinase C (PKC) inhibitor, that might be unspecific 
and therefore was not further investigated. The other three inhibitors, shikonin, 
dihydrotanshinone and cryptotanshinone (Figure 3.4) have a low IC50 value in the micro-
molar range, and they are not known as sirtuin inhibitors so far.  
 
 
Figure 3.4: Identification of potential SirT1 inhibitors from the BIOMOL library 
SirT1 deacetylation activity was strongly inhibited by shikonin, dihydrotanshinone and cryptotanshinone. SirT1-
dependent MAL deacetylation was measured by the MAL deacetylation assay. The control reaction containing 
DMSO was set to 100 %. IC50 values and curve fitting were performed using GraphPad. Values correspond to 
the average enzyme activity of three independent experiments ± standard deviation.  
 
ChemBioNet library 
Next, we screened the ChemBioNet library, which is located at the FMP (Screening Unit of 
the Leibniz-Institute for Molecular Pharmacology Berlin) and consists of approximately 
18.000 compounds, for SirT1 activators and inhibitors. For this screen, several measurements 
were required in advance to optimize the MAL deacetylation assay, including the 
improvement of the deacetylation rate. Therefore, a series of measurements were performed, 
for instance different concentrations of buffer components (Tween, BSA and DTT) as well as 
MAL and enzyme concentrations were tested. Finally, higher concentrations of DTT 
(dithiothreitol; 1mM) and SirT1 enzyme (approximately 1 µM) improved the deacetylation of 
MAL. Furthermore, the procedure of the assay had to be tested with the automatic pipetting 
system, each solution was added to the plate with a different pipetting system to prevent 
contaminations.  
The first screen of this library achieved 352 potential results, both inhibitors and activators 
that were further validated as for the compounds of the BIOMOL library. The analysis of the 
screen was performed using a computer analysis program of the Screening Unit in 
collaboration with computer analysts of the FMP. A z-factor that quantified the suitability of 
an assay for use in a high-throughput screen was determined and thereof potential activators 
and inhibitors were determined. For the validation of the first screen, different concentrations 
(ranging from 0.2 to 50 µM) of each of theses 352 potential modulators were measured again 
Results 
 48 
using the MAL deacetylation assay. To test for autofluorescence of each compound, the 
fluorescence was measured directly after compound addition and before the substrate was 
added. The test for trypsin inhibition was performed after validation in a separate 
measurement with the deacetylated substrate ML. This second screen also resulted many 
candidates. With help of a chemist of the FMP (Dr. Edgar Specker) a few candidates were 
eliminated based on their properties such as reactivity and specificity. Finally, 15 inhibitors 
and 13 activators were obtained, and most of them, 14 inhibitors and 12 activators were 
subsequently reordered from ChemDiv, Asinex or Enamine for further analysis.  
During my further thesis, we have concentrated on the inhibitors that we identified in both 
screens. Because of the known problems with activators in the MAL deacetylation assay, the 
sirtuin inhibitors seemed to be promising candidates worth pursuing, whereas the activators 
may be affected by the fluorophore on the MAL substrate. The activators were independently 
pursued by Louisa Hill during her master thesis (overview in 3.4), and some of her results 
have been followed up on in this thesis.  
The inhibitory effect of the 14 compounds was confirmed using the MAL deacetylation assay 
to generate IC50 values and inhibition curves of each compound (Figure 3.5). For the purpose 
of this thesis, the compounds were sorted by increasing IC50 values and labeled A to M. The 
influence on SirT1 activity of different concentrations ranging from 0.49 to 250 µM of each 
compound was measured by MAL deacetylation assay in three independent experiments. The 
IC50 values and the curve fitting were performed with help of the computer program 
GraphPad Prism. Suramin is a well-known inhibitor of SirT1 (Trapp et al. 2007) and was used 
as control here. In our MAL deacetylation assay, it had an IC50 value of 4.7 µM, which is 
somewhat higher than in other publications described (0.6 µM (Sanders et al. 2009) or 297 
nm (Trapp et al. 2007)), but this could be through the use of different assay conditions and 
other substrates. Except of one compound (N), the inhibitory effect of the inhibitors that we 
had reordered could be confirmed. All of them showed a dose-dependent inhibition of SirT1 
deacetylase activity, the IC50 values vary from 2.4 µM (compound A) to 173.2 µM 
(compound M). These results indicated that we had identified a total of 16 potential SirT1 
inhibitors from the BIOMOL and the ChemBioNet library.  
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Figure 3.5: Identification of potential SirT1 inhibitors from the ChemBioNet library 
The effect of the inhibitors on SirT1-dependent MAL deacetylation was measured by the MAL deacetylation 
assay. Compound labeling and order are corresponding to their IC50 values. The control reaction containing 
DMSO was set to 100 %. IC50 values and curve fitting were performed using GraphPad. Values correspond to 
the average enzyme activity of three independent experiments ± standard deviation. To the right of the IC50 
curves the chemical structure of each compound is shown. The chemical structure of suramin is not shown here 
due to the lack of space (see 1.6.3 Figure 1.11).  
 
3.1.3 Establishment of an HPLC-based p53 deacetylation assay 
As mentioned above the MAL deacetylation assay is controversial, because the fluorophore 
that is coupled to the substrate influences the activity of SirT1. Although the activators 
probably more affected by the fluorophore than the inhibitors, we sought to establish a 
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deacetylase assay in our lab that is independent of the presence of the fluorophore. The assay 
is described in (Liu et al. 2008), and for this we used a p53-derived peptide (aa 368 – 386 of 
p53) that carries an acetylated lysine (K382) and lacks any fluorophore as substrate. The 
sirtuin-dependent deacetylation of this peptide was measured by HPLC (high performance 
liquid chromatography) -based separation of the acetylated and the deacetylated peptide. 
Because of their different retention time on the column, it was possible to separate the 
peptides (Figure 3.6). The peptides were eluted from the HPLC column using an increasing 
acetonitrile gradient (1 % to 35 %) over 30 min. The percentage of deacetylation was 
calculated by dividing the area under the peak of the deacetylated peptide by the sum of the 
areas under the peak of both peptides. 
 
Figure 3.6: Separation of p53 (aa 368-386) and Ac-p53 (aa 368-386) by HPLC 
The separation of Ac-p53 and p53 peptides is shown as an overlay of two samples that were both eluted from the 
HPLC column by a linear gradient of 1 % to 35 % acetonitrile in 0.1 % trifluoroacetic acid over 30 min. The 
peptides were detected and quantified using a UV detector at a wavelength of 214 nm. 
 
The reaction conditions for the HPLC-based p53 deacetylation reaction were nearly the same 
as in the MAL deacetylation assay, except that the reaction time was only 30 min instead of 
4 h. The p53 peptide is a substrate of preference for SirT1, and therefore it was deacetylated 
more quickly than the MAL substrate. The reaction time was calculated such that 50 % of the 
substrate was deacetylated by SirT1. As previously published (Beher et al. 2009; Pacholec et 
al. 2010), resveratrol did not enhance the activity of SirT1 in this p53 deacetylation assay. 
However, suramin was able to inhibit SirT1 activity in this HPLC-based p53 deacetylation 
assay, but to a lesser extent than in the MAL deacetylation assay (Figure 3.7).  
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3.1.4 Effect of inhibitors on SirT1-dependent p53 deacetylation 
Subsequently, the inhibitory effect of each compound on SirT1 activity was measured by the 
HPLC-based p53 deacetylation assay. All in all, several of the inhibitors also showed some 
degree of inhibition of SirT1 in the p53 deacetylation assay (Figure 3.7), although a higher 
compound concentration was needed in comparison to the MAL deacetylation assay. The IC50 
values that were achieved in the MAL deacetylation assay (Figure 3.7, right side) are much 
lower in comparison to the inhibitor concentrations that were needed to inhibit 50 % of the 
SirT1 activity in the p53 deacetylation assay.  
 
Figure 3.7: Influence of inhibitors on SirT1-dependent p53 deacetylation 
The inhibitory effect of 20 µM and/or 50 µM of each compound on SirT1 was analyzed by HPLC-based p53 
deacetylation assay and displayed as % of SirT1 activity. DMSO was used as control and set on 100 %. Values 
correspond to the average enzyme activity of three independent experiments  standard deviation, except of the 
values of suramin, shikonin, dihydrotanshinone, cryptotanshinone and compound B (20 µM), which correspond 
to one experiment. The IC50 values of each inhibitor that were achieved in the MAL deacetylation assay are 
displayed on the right side for comparison. 
 
Suramin, which was used as control, showed only 50 % inhibition of SirT1 at 20 µM in 
comparison to its IC50 value of 4.7 µM in the MAL deacetylation assay. The inhibitors 
shikonin, dihydrotanshinone, cryptotanshinone and compound B showed the strongest 
inhibition to approximately 50-60 % of SirT1 activity at a concentration of 20 µM. 
Compound F inhibited approximately 50 % of SirT1-dependent p53 deacetylation, whereas 
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the compounds A, C, H and K failed to inhibit 50 % SirT1 activity at a concentration of 50 
µM. The inhibitors D, E, G, I, J, L and M showed hardly inhibition of SirT1-dependent p53 
deacetylation. However, it has been reported that SirT1 has poor affinity for the substrate 
MAL (Heltweg et al. 2003). Most likely, for this reason, a lower concentration of inhibitor is 
necessary to inhibit the deacetylation of MAL in comparison to p53 deacetylation, which is 
the preferred substrate (Pan et al. 2012). In support of this theory, it is been reported that the 
fluorophore on the substrate decreases the binding affinity of SirT1 for this substrate 
(Kaeberlein et al. 2005). This suggests that the results of the p53 deacetylation assay are more 
potent than the IC50 values of the MAL deacetylation assay. 
 
3.2 In vitro characterization of potential SirT1 inhibitors  
3.2.1 Generation of N-terminal truncations of SirT1 
Several studies have shown that the N- and C-terminal regions have an influence on the 
deacetylase activity of sirtuins. They play important roles in acetyl-lysine and NAD+ binding 
(Zhao et al. 2003a), subnuclear distribution (Cockell et al. 2000) and interaction with cellular 
binding partners (Cuperus et al. 2000; Tennen et al. 2010). Furthermore, the ability of 
resveratrol or other STACs to activate SirT1 is dependent on the presence of the N-terminus 
(Milne et al. 2007). Based on theses results, we asked whether this was also the case for the 
sirtuin inhibitors identified here. To determine whether they also interacted with the N-
terminus of SirT1, a series of SirT1 truncations in analogy to (Milne et al. 2007) were 
generated. Five (SirT1_A, B, D, E and F) of seven constructs that are truncated at the N-
terminus (Figure 3.8A) could be successfully expressed and purified from E. coli. The 
purified fractions were subjected to SDS-PAGE gel electrophoresis and stained with 
Coomassie blue to determine the amounts of purified protein of each construct (Figure 3.8B). 
The protein purification of construct SirT1_G was not efficient enough to observe sufficient 
amounts of proteins in the Coomassie blue stained SDS-PAGE gel. The SirT1 truncations 
were analyzed by Western blotting with α-poly-His antibody. As shown in Figure 3.8B, the 
constructs ran slightly above the expected size (SirT1_A 57.3 kDa, SirT1_B 55.5 kDa, 
SirT1_C 50.0 kDa, SirT1_D 49.5 kDa, SirT1_E 49.0 kDa and SirT1_F 48.4 kDa), which was 
determined using ExPASy (http://web.expasy.org/protparam/). Subsequently, the deacetylase 
activity of the purified SirT1 truncations was determined by the MAL deacetylation assay 
(Figure 3.9). Five SirT1 truncations (SirT1_A, SirT1_B, SirT1_D, SirT1_E and SirT1_F) 
showed deacetylase activity in the MAL deacetylation assay, though to varying degrees. 
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Figure 3.8: Generation of truncated SirT1 constructs 
Different constructs of SirT1 with varying length of the N-terminal domain (A) were generated to characterize 
potential binding sites of SirT1 inhibitors and activators. The catalytic core domain (gray) is located between 
amino acid 244 and 498. Five of these constructs were successfully purified from E. coli by His-tag purification. 
(B) Coomassie-stained SDS-PAGE gel of purified truncations of SirT1. SirT1-containing fractions were 
identified by Western blotting with α-poly-His antibody.  
 
Although construct SirT1_C showed a signal in the Western blot against α-His antibody, the 
amount of purified protein of the constructs SirT1_C as well as SirT1_G were insufficient to 
observe a deacetylase activity in the MAL deacetylation assay.  
 
Figure 3.9: Deacetylase activity of SirT1 truncations 
The deacetylase activity of truncated SirT1 constructs was measured by the fluorescence-based assay. Of each 
construct a serial dilution was performed. The values correspond to the average enzyme activity of a three-fold 
determination ± standard deviation of one experiment. 
 
To test whether these varying degrees of deacetylase activity depend on the different amounts 
of purified protein, the same amount of protein was determined by Bradford and Coomassie 
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blue stained SDS-PAGE and put in the MAL deacetylation assay, whereby the activity of full-
length SirT1 was set to 100 % (Figure 3.10). The constructs SirT1_A and SirT1_B had more 
or less the same deacetylase activity as full-length SirT1, whereas the constructs SirT1_D and 
especially SirT1_E showed a higher deacetylase activity as the full-length SirT1. The activity 
of the shortest construct SirT1_F was strongly reduced in comparison to the full-length SirT1, 
suggesting that the N-terminal region of SirT1 has an influence on the deacetylase activity of 
SirT1. For further experiments, the final dilution of each construct was chosen such that an 
activity of approximately 10.000 RFU (relative fluorescence unit) was achieved. Thus, the 
truncations were diluted as follows: SirT1_A and SirT1_B 1:100, SirT1_D 1:250, SirT1_E 
1:400 and SirT1_F 1:40. 
 
Figure 3.10: SirT1 truncations had different deacetylase activity 
The amount of protein was determined by Coomassie blue stained SDS-PAGE gel, the respective full-length 
SirT1 protein band is highlighted by the arrow. For the construct SirT1_E two samples were loaded on the gel. 
The deacetylase activity of each construct was measured in the MAL deacetylation assay. The activity of full-
length SirT1 was set to 100 %. The values correspond to the average enzyme activity of a four-fold 
determination ± standard deviation of one experiment. 
 
Furthermore, the influence of resveratrol and suramin on the SirT1 truncations was measured 
by the MAL deacetylation assay (Figure 3.11). Resveratrol at a concentration of 50 µM 
stimulated the deacetylation activity of the truncations SirT1_A and SirT1_B, which both 
have an extended N-terminal region. The shorter constructs SirT1_D, SirT1_E and SirT1_F 
were not activated by resveratrol. These results are in agreement with published data, where it 
has been shown that the N-terminal region is required for the enhancement of SirT1 activity 
by resveratrol (Milne et al. 2007). In contrast, suramin was able to inhibit all SirT1 
truncations to approximately 50 % or more. This indicates that the N-terminus is not required 
for the inhibition by suramin, suggesting that suramin itself does not interact with the N-
terminal region of SirT1.  
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Figure 3.11: Influence of resveratrol and suramin on SirT1 truncations 
The influence of resveratrol (50 µM) and suramin (6.25 µM) on SirT1 truncations was measured by 
fluorescence-based assay. The control reactions of each construct containing DMSO and were set to 100 %. 
Values correspond to the average enzyme activity of three independent experiments  standard deviation.  
 
3.2.2 Deacetylase activity of further sirtuin family members in the MAL 
deacetylation assay 
For further characterization of the inhibitors identified in this work, the Sir2 protein from S. 
cerevisiae (ySir2) was also expressed and purified from E. coli using His-tag purification, and 
its activity was measured by the MAL deacetylation assay (Figure 3.12). ySir2 showed 
deacetylase activity and could be inhibited to approximately 50 % by 125 µM splitomicin, 
which is a well-known inhibitor of ySir2 (Bedalov et al. 2001). However, Bedalov et al. 
determined an IC50 value of 60 µM for ySir2 using an acetylated H4 peptide, whereas in our 
MAL deacetylation assay a higher concentration of splitomicin was needed to inhibit 50 % of 
ySir2 activity. 
 A  B 
 
Figure 3.12: Purification and deacetylase activity of ySir2 
The Sir2 protein from S. cerevisiae (ySir2) was expressed in E. coli and purified by His-tag purification. (A) 
Coomassie stained SDS-PAGE gel with 10 µl of the purified fraction. The identification of the ySir2 protein was 
performed by Western blotting with α-poly-His antibody. (B) The deacetylase activity of ySir2 purified from E. 
coli was measured by the MAL deacetylation assay and could be inhibited by 125 µM of splitomicin, a known 
inhibitor of ySir2. The control reaction containing DMSO was set to 100 %. Values correspond to the average 
enzyme activity of three independent experiments ± standard deviation. 
 
We also obtained purified samples of further members of the sirtuin family (SirT2 to SirT7; 
BIOZOL) except SirT4, which has no obvious deacetylase activity (Haigis et al. 2006). Their 
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deacetylase activity was measured by the MAL deacetylation assay and compared with that of 
purified SirT1 (Figure 3.13).  
 
 
Figure 3.13: Deacetylase activity of human sirtuins in the MAL deacetylation assay 
The deacetylase activity of further sirtuin family members was measured by the MAL deacetylation assay. Of 
each construct a serial dilution was performed. The values correspond to the enzyme activity of one experiment. 
 
Next to SirT1, only SirT2 and SirT3 were able to deacetylate MAL in the fluorescence-based 
assay. However, it is not surprising that MAL is unsuitable as a substrate for the other 
sirtuins. So far, the only known substrates of SirT6 and SirT7 are histones (Michishita et al. 
2008; Barber et al. 2012) and maybe they need a more complex protein than a simple lysine to 
recognize it as substrate. SirT5 has only weak deacetylase activity (Du et al. 2011), which 
may be insufficient for the MAL deacetylation assay. Similar to the SirT1 truncations, for 
further experiments SirT2 and SirT3 were diluted such that an activity of approximately 
10.000 RFU was achieved (SirT2 1:100 and SirT3 1:30).  
 
3.2.3 Influence of inhibitors on further sirtuin family members 
The influence of the 16 potential SirT1 inhibitors that were identified in this work was 
measured with the SirT1 truncations, SirT2, SirT3 and ySir2 (Figure 3.14) in order to gain 
insight into their specificity and to get further information about their interaction sites with 
small molecule compounds that influence their activity. 50 µM of each inhibitor was used in 
the MAL deacetylation assay.  
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Figure 3.14: Influence of inhibitors on further sirtuin members 
The effect of the inhibitors on each sirtuin was analyzed by the MAL deacetylation assay and displayed as % of 
activity in the control reaction. The control reaction contained DMSO and was set to 100 %. 50 µM of each 
inhibitor (diluted in DMSO) was used. Values correspond to the average enzyme activity of three to six 
independent experiments ± standard deviation. 
 
The compounds shikonin, dihydrotanshinone, cryptotanshinone, A and B were SirT1-specific 
inhibitors, because they showed the strongest inhibition of SirT1 and their truncations that 
were inhibited to approximately 20 % - 30 %. Except for B, they also showed strong 
inhibition of ySir2, which may not be surprising, because SirT1 is the closest homolog of 
ySir2. These results also indicate that shikonin, dihydrotanshinone, cryptotanshinone as well 
as A and B may not interact with the N-terminus of SirT1, because the truncations were 
inhibited as strongly as full length SirT1 in the MAL deacetylation assay. The compounds C, 
F, G, H, I and M showed the strongest inhibition of full length SirT1 and the shortest 
construct, SirT1_F (235-664). Perhaps theses compounds interact with and inhibit the SirT1 
core domain, and these interactions become stronger after deletion of the N-terminal region. 
Furthermore, the strong inhibition of SirT1_F could also be due to the low deacetylase 
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activity of the short construct. In the case of compound D, it seems that it interacts with the 
first 225 amino acids of N-terminal region, because it inhibited only full length SirT1 as well 
as the constructs with an extended N-terminus, SirT1_A (156-664) and SirT1_B (172-664). 
The shorter constructs SirT1_D (225-664) and SirT1_E (230-664) were not affected by the 
inhibitor D. Furthermore, compound D also showed a strong inhibition of SirT2 that has an 
extended N-terminus in comparison to SirT3, whose active form lacks a N-terminal region. 
However, D inhibited ySir2 to a lesser extent than SirT1, although ySir2 also has an extended 
N-terminus, but it is known that the N-terminal region of sirtuins is not conserved. This 
suggests that compound D interacts with a specific site of the N-terminus of SirT1 and SirT2. 
Compound E and J appear to be unspecific sirtuin inhibitors, because they inhibited more or 
less all SirT1 truncations, ySir2 as well as SirT2 and SirT3. Compound K and especially L 
showed the strongest inhibition of SirT2. L inhibited SirT2 activity to approximately 10 % at 
a concentration of 50 µM. This suggests that compound L could be a potent SirT2 inhibitor. 
For this reason SirT2-dependent MAL deacetylation was measured with different 
concentrations of L and an IC50 curve was performed (Figure 3.15). Remarkably, compound 
L showed approximately a six-fold stronger inhibition of SirT2 (IC50 = 18.5 µM) than of 
SirT1 (IC50 = 118,4 µM; Figure 3.5).  
 
 
Figure 3.15: Compound L is a potent SirT2 inhibitor 
SirT2-dependent MAL deacetylation was measured by fluorescence-based assay. The control reaction containing 
DMSO was set to 100 %. IC50 values and curve fitting were performed using GraphPad. Values correspond to 
the average enzyme activity of three independent experiments ± standard deviation.  
 
The influence of compound L on SirT2 activity was also measured by the HPLC-based p53 
deacetylation assay. Notably, the inhibition of p53 deacetylation by L is comparable with the 
inhibition of MAL deacetylation in the fluorescence-based assay (Figure 3.16). At 20 µM 
compound L inhibited SirT2 activity by more than 50 %, and this value was comparable with 
the IC50 value of 18.5 µM in the MAL deacetylation assay. These results support the idea that 
compound L is a potent SirT2 inhibitor.  
Results 
 59 
 
Figure 3.16: Inhibitory effect of compound L in the p53 deacetylation assay 
The inhibitory effect of 20 µM and 50 µM of compound L on SirT2 activity was measured by HPLC-based p53 
deacetylation assay and displayed as % of SirT2 activity. DMSO was used as control and set to 100 %. Values 
correspond to the average enzyme activity of three independent experiments ± standard deviation.  
 
3.2.4 Sirtuin inhibition by derivates of compounds H and L 
Since we so far had identified potential sirtuin inhibitors, we were interested to develop them 
further for in vivo use. Based on the in vitro as well as in vivo results that will be described 
later, compound H and L appeared to be of particular interest. Based on their chemical 
structure, it can be hypothesized that they are cell permeable and do not display unspecific 
reactivity (Prof. Dr. M. Kaiser, UDE, personal comment) Based on this assessment, we 
obtained derivates of compound H and L in order to perform a structure-function analysis and 
to speculate about the part of their chemical structure that is required for their inhibitory 
effect. In case of compound H, we were able to obtain two derivates (H-I and H-II), that are 
structurally distinct from each other. These derivates shared different parts of the structure 
with compound H. In Figure 3.17A, the structure of H is divided into two parts by the dashed 
line. The structure above the dashed line is present in H-I, whereas the part below the line is a 
component of H-II. The inhibitory effect of these two derivates was measured in the MAL 
deacetylation assay (Figure 3.17B). Interestingly, while H-I showed a slight inhibition of 
SirT1 deacetylase activity (IC50 = 231.9 µM), H-II was unable to inhibit SirT1 at 
concentrations as high as 250 µM. This indicated that the structure part of compound H above 
the dashed line is necessary for the inhibitory effect on SirT1 in contrast to the structure part 
below the line. However, in view of the high IC50 value of H-I, the structure below the dashed 
line also contributed to acting, it might also contributed to the inhibitory effect, but to a lesser 
extent than the structure above the dashed line. Probably, the sum of all ring systems of H as 
well as H-I is necessary for the generation of π-π interactions with the SirT1 enzyme and to 
inhibit SirT1. Perhaps for this reason, compound H is a more potent inhibitor than H-I. 
However, to verify this theory more derivates of compound H with different substitutes would 
be necessary. 
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Figure 3.17: Inhibitory effect of H derivates on SirT1 dependent MAL deacetylation 
(A) Chemical structure and IC50 curve of compound H. The dashed line within the structure indicates where the 
substituents were changed to generate new derivates. (B) The inhibitory effect of H-I and H-II on SirT1 was 
measured by fluorescence-based assay. The control reaction containing DMSO was set to 100 %. IC50 values and 
curve fitting were performed using GraphPad. Values correspond to the average enzyme activity of three 
independent experiments ± standard deviation. To the right of the IC50 curves the chemical structure of each 
compound is pictured. 
 
We furthermore were able to obtain four derivates (L-I to L-IV) of compound L that were 
structurally similar to one another, but had different substituents attached at the 
carboxamidegroup. Since L showed the strongest inhibition with SirT2, the inhibitory effect 
on SirT2 was determined by the MAL deacetylation assay (Figure 3.18). Strikingly, L-I had 
an IC50 value of 3.8 µM and thus showed a stronger inhibition of SirT2 than compound L 
(IC50 = 18.5 µM). L-II with an IC50 value of 18.7 µM had a similar inhibitory effect as 
compound L. L-III and L-IV had a weak or no inhibitory effect on SirT2. These results 
indicate that the addition of an aromatic ring increases the binding affinity of compound L for 
SirT2.  
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Figure 3.18: Inhibitory effect of L derivates on SirT2 dependent MAL deacetylation 
The inhibitory effect of L derivates on SirT2 activity was measured by MAL deacetylation assay. The control 
reaction containing DMSO was set to 100 %. IC50 values and curve fitting were performed using GraphPad. 
Values correspond to the average enzyme activity of three independent experiments ± standard deviation. To the 
right of the IC50 curves the chemical structure of each compound is pictured. The IC50 curve and chemical 
structure of L are displayed for comparison. The dashed line around the carboxamidegroup highlight where the 
substituents were added. 
 
The inhibitory effect of compound L-I on SirT2 was also measured using the HPLC-based 
assay with p53 as substrate. Compared to compound L, L-I showed a stronger inhibition of 
SirT2 activity in the p53 deacetylation assay (Figure 3.19). At a concentration of 20 µM L-I 
inhibited SirT2 deacetylase activity to approximately 20 % and to 10 % at 50 µM. This 
showed that compound L-I is a more potent SirT2 inhibitor than compound L. Similar to 
compound H, the aromatic pyridine ring could generate additional π-π interactions with the 
enzyme, and this may lead to a stronger binding affinity of compound L-I for SirT2. 
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Figure 3.19: Compound L as well as L-I inhibited p53 deacetylation 
The inhibitory effect of 20 µM and 50 µM of compound L and L-I on SirT2 was analyzed by HPLC assay and 
displayed as % of SirT2 activity. As control DMSO was used and set on 100 %. Values correspond to the 
average enzyme activity of three independent experiments ± standard deviation. 
 
3.3 Characterization of sirtuin inhibitors in vivo  
3.3.1 Increased apoptosis after inhibitor treatment 
Sirtuins are known to play important roles in cell survival, apoptosis and cancer development 
due to their broad range of targets. Furthermore, SirT1 as well as SirT2 inhibitors such as 
cambinol, tenovin-6 and sirtinol have been shown to have high anticancer potential (Heltweg 
et al. 2006; Ota et al. 2006; Lain et al. 2008). For this reason, we wanted to analyze the in vivo 
influence and the anticancer potential of the inhibitors identified in this study. For this 
approach we used the human lung cancer cell line A549. This cell line was treated with 
different concentrations of each inhibitor. After treatment for 48 h, cell apoptosis was 
measured by determining the number of cells with a DNA content less than G1-phase cells 
(Sub-G1) by FACS analysis.  
The treatment with the inhibitors shikonin, dihydrotanshinone as well as cryptotanshinone led 
to a strong increase of apoptosis at low concentrations of 1-2 µM, which corresponds to the 
IC50 value of 1.7 µM and 3.4 µM determined in the MAL deacetylation assay. However, these 
three inhibitors have a very reactive chemical structure and therefore they might interact with 
multiple cellular targets and not inhibited SirT1 specifically (Prof. Dr. M. Kaiser, UDE, 
personal comment). As shown in Figure 3.20, the inhibitors C and H showed a moderate 
increase of apoptosis to approximately 30 %, whereas compound B induced a slight increase 
to 10 % cell death and compound F lead a strong increase of apoptosis to 90 % at 
concentrations of 2-5 µM. Because of their ability to induce cell death of cancer cells the in 
vivo influence of the inhibitors B, C, F as well as H were further analyzed. Additionally, since 
compound L and L-I showed a strong inhibition of SirT2 in vitro, the in vivo influence of 
both compounds was also analyzed at higher concentrations, because compound L showed no 
effect on A549 cells at a concentration of 5 µM (Figure 3.20).  
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Figure 3.20: Cell death of A549 cells after inhibitor treatment 
The lung cancer cell line A549 was treated with different concentrations of the inhibitors identified in this study. 
Apoptosis was measured by FACS analysis and displayed as % cell death. Values correspond to one experiment. 
 
For further analysis the A549 cells were treated again with these six compounds C, F, H as 
well as L and L-I, but in combination with the chemotherapeutic agent etoposide (VP-16). 
Etoposide is a topoisomerase II inhibitor and causes DNA single-strand and double-strand 
breaks. Cancer cells are more affected by etoposide than normal cells, because they divide 
more rapidly (Hande 1998). This procedure causes DNA mismatches and promotes apoptosis 
of the cancer cells. It is known that apoptosis in response to stress, among others, is dependent 
on the tumor suppressor p53 (Levine 1997; Prives and Hall 1999) that can be inhibited by 
SirT1 deacetylation. Therefore, cell survival is promoted in response to DNA damage by 
inhibiting p53-dependent apoptosis (Luo et al. 2001). Several cancer forms including lung 
cancer cells show increased levels of SirT1 protein (Fraga and Esteller 2007; Stunkel et al. 
2007) and this overxpression of SirT1 may be one reason for the resistance of cancer cells 
against chemotherapeutic agents, such as VP-16. In our further experiments, we found that 
only 7 % of untreated A549 cells died after treatment with VP-16, suggesting that they are 
resistant against VP-16. For further experiments, the A549 cells were treated with different 
concentrations of each inhibitor alone and in combination with VP-16 for 48 h. The 
hypothesis was that, if the compounds inhibit SirT1 in the cell, then p53 is active and we 
should observe an increase of apoptosis. Of the six inhibitors, three compounds H, L as well 
as L-I showed an additional increase of apoptosis after combined treatment with VP-16. The 
other inhibitors C and F showed no differences between the treatment with or without VP-16 
at higher concentration of 5 µM, and compound B showed no further increase of apoptosis 
(Figure 3.21). 
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Figure 3.21: Influence of compound B, C and F on the cancer cell line A549 
The A549 cell line was treated with different concentrations of the inhibitor B, C and F alone (dark gray bar) or 
in combination with 1 µM VP-16 (light gray bar). Apoptosis was measured by FACS analysis and displayed as 
% cell death. Values correspond to one experiment.  
 
Compound H showed in combination with VP-16 a slight additional increase of apoptosis at 
low concentrations up to 5 µM in comparison to the treatment with H alone (Figure 3.22A). 
Because of this additional increase of apoptosis after combined treatment with VP-16, we 
sought to determine whether this effect may be p53-dependent. For this reason, we used the 
human lung cancer cells H1299, which have a partial deletion of the p53 gene and cannot 
express the p53 protein. Surprisingly, after treatment with compound H alone, apoptosis 
increased up to 45 % at 5 µM and up to 50 % at 10 µM, which represented a higher cell death 
rate than in the A549 cells. However, in combination with VP-16, apoptosis was decreased to 
approximately 20 %, a degree that was comparable to that in A549 cells (Figure 3.22B). Of 
course both cell lines have more differences than the expression of p53 protein, but this 
results indicated that, contrary to expectation, apoptosis mediated by compound H might not 
be p53-dependent.  
 
 
Figure 3.22: Compound H induced apoptosis of cancer cells 
Lung cancer cell line A549 (A), which is p53 wild type, and H1299 (B), which is p53 negative, were treated with 
different concentrations of compound H alone (dark gray bar) or in combination with 1 µM VP-16 (light gray 
bar). SubG1 phase was measured by FACS analysis and displayed as % cell death. Values correspond to the 
average cell death of three independent experiments ± standard deviation. 
 
In contrast to compound H, compound L as well as L-I induced a further increase of 
apoptosis when combined with VP-16 in comparison to the treatment with the compound 
alone (Figure 3.23). In both cases, apoptosis was increased from approximately 5 % with VP-
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16 alone to approximately 20 % at the highest compound concentration of 20 µM. This effect 
was not very pronounced, but strikingly this effect could not be observed in H1299 cells. 
After treatment with the inhibitors alone, apoptosis increased to approximately 10 % at the 
highest concentration of 20 µM, which was comparable to the cell death in A549 cells. 
However, the combined treatment with VP-16 did not lead to a further increase of apoptosis. 
On the contrary, apoptosis of H1299 cells was decreased to approximately 5 % after treatment 
with 20 µM of compound L-I in combination with VP-16. Although L-I had a better IC50 
value in vitro than L, its effect to induce apoptosis of A549 cells was comparable to the effect 
of L. In view of their chemical structure both may be metabolized in the cell in the same 
manner. This suggested that both inhibitors had s similar in vivo influence on the cells, which 
might be p53-dependent.  
 
 
Figure 3.23: Influence of compound L on the cancer cell lines A549 and H1299 
Lung cancer cell lines A549 and H1299 were treated with different concentrations of compound L (A) or L-I (B) 
alone (dark gray bar) or in combination with 1 µM VP-16 (light gray bar). SubG1 phase was measured by FACS 
analysis and displayed as % cell death. Values correspond to the average cell death of three independent 
experiments ± standard deviation. 
 
3.3.2 Sirtuin inhibitors decreased cell viability and proliferation 
To further characterize the anticancer potential of the three inhibitors H, L and L-I and to 
determine their ability to decrease cancer cell development, additional experiments such as 
proliferation and cell viability measurements were performed. For proliferation 
measurements, approximately 50.000 cells per dish were plated out and incubated at 37 °C 
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until the cells were adherent. Subsequently, the cell number of one dish that represents the 
time point before the treatment (0 h) was counted, whereas the other cells were treated with 
the inhibitor. After an incubation time of 48 h, the cell number was counted and the cell 
number of untreated cells containing DMSO was set to 100 % (Figure 3.24). Because of the 
high toxicity of compound H and to compare the results with L as well as L-I, a concentration 
of 10 µM was used instead of 20 µM as was the case for the FACS analysis (Figure 3.23). All 
three inhibitors decreased cell proliferation, whereby compound L showed the weakest effect. 
In A549 cells, compound L deceased cell proliferation by 40 %, but in H1299 only by 10 %. 
This suggested that the in vivo effect of compound L is not completely, but may be partly 
p53-dependent. Compound L-I had a stronger inhibitory effect on cell proliferation in both 
cell lines, where cell proliferation was decreased to approximately 20 % - 30 %. Compound H 
showed in both cell lines the same effect; it decreased cell proliferation to approximately 
10 %. These results suggested that compound H as well as L-I were able to strongly reduce 
cancer cell proliferation independently of the p53 protein. In the future experiments, it should 
be determined whether this potential is limited to cancer cells.  
 
 
Figure 3.24: Cell proliferation was decreased after inhibitor treatment 
Both cell lines A549 and H1299 were treated with 10 µM of compound H, L as well as L-I and after 48 h the cell 
number was counted. The cell number before the inhibitor treatment is displayed as 0 h. The negative control 
(n. C.) represents cells that were treated with DMSO and was set to 100 %. Values correspond to the average cell 
number of three independent experiments ± standard deviation. 
 
For measurements of cell viability, we used the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) assay, which is a sensitive assay to measure reduction of cell 
viability, when metabolic events lead to apoptosis or necrosis. MTT is a yellow dye that is 
reduced to insoluble purple formazan dye crystals by metabolically active cells. Through the 
addition of solubilisation buffer (0.01 M HCl, 10 % SDS) the crystals were solubilised, and its 
absorbance was measured at 550-600 nm using a spectrophotometer. Both cell lines A549 and 
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H1299 were treated with different concentration (up to 10 µM) of the three inhibitors for 48 h 
and cell viability was determined by the MTT assay. As shown in Figure 3.25, all three 
inhibitors decreased cell viability to 50 % at the highest concentration of 10 µM. However, 
compound L and L-I did not induce as sharp a decrease of viability at lower concentrations as 
compound H, and the viability of H1299 cells was slightly higher than that of A549 cells after 
treatment with L or L-I.  
 
Figure 3.25: Cell viability was reduced after inhibitor treatment 
The lung cancer cell lines A549 and H1299 were treated with different concentrations of compound H, L and L-I 
for 48 h. Afterwards, cell viability was measured by MTT assay. The control reaction containing DMSO was set 
to 100 %. Values correspond to the average cell viability of three independent experiments ± standard deviation. 
 
These results suggested that all three inhibitors were able to decrease cell viability, supporting 
the results of the proliferation measurements, which showed that all inhibitors more or less 
reduced cell proliferation, though this was not completely dependent of the p53 protein. 
However, SirT1 as well as SirT2 have a broad range of targets that are responsible for cell 
cycle progression and that could be affected through the inhibitor treatment. It could also be 
that the inhibitors not directly inhibited SirT1 or SirT2 in vivo, but also other cell components 
that decrease the cell viability.  
 
3.3.3 Induced apoptosis was partly dependent on p53 
The results of apoptosis induced by compound L as well as L-I suggested that the in vivo 
effects of both inhibitors might be p53-dependent. In contrast, the results of the MTT assay 
showed that L as well as L-I could reduce cell viability to approximately 50 % in both cell 
lines and this therefore might not be p53-dependent. However, similar to SirT1, SirT2 affects 
a variety of different substrates that are involved in many biological processes, such as cell 
cycle progression and apoptosis. Through the inhibitor treatment, not only p53 may be 
affected, but the increase of apoptosis could be p53-dependent. And to assess this, we 
obtained H1299 (MS48) cells that were transfected with a p53 plasmid that carried a fusion of 
human p53 with a modified estrogen receptor ligand-binding domain (ERTM = estrogen 
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receptorTamoxifen Mutant; Prof. M. Schuler, University Hospital Essen). The H1299 (MS48) cells 
expressed the p53-ERTM gene, but p53 remained inactive until the synthetic steroid 
4-hydroxytamoxifen was added and unmasked the p53-ERTM fusion protein (Littlewood et al. 
1995).  
The expression of the p53-ERTM protein in H1299 (MS48) cell was determined by Western 
blotting using an α-p53 antibody. As shown in Figure 3.26, we were able to detect the p53-
ERTM protein in the H1299 (MS48) cells in comparison to the wild-type H1299 cells. The 
p53-ERTM protein migrated at a higher molecular weight than the 53 kDa of p53, because of 
the fusion with the estrogen receptor ligand-binding domain.  
 
Figure 3.26: H1299 (MS48) cells expressed p53 protein 
The expression of p53 protein was determined by Western blotting in whole cell extract with α-p53 antibody. 
The antibody α-tubulin was used as loading control.  
 
The H1299 (MS48) cells were treated in the same manner as the H1299 and A549 cells with 
different concentrations of the inhibitors alone and in combination with VP-16, and apoptotic 
cells were measured by FACS analysis. To determine whether the presence of the p53-ERTM 
fusion plasmid itself had an influence on the cells, we first performed the measurements 
without the tamoxifen treatment. As shown in (Figure 3.27), the H1299 (MS48) cells induce 
no additional apoptosis after combined treatment with compound L or L-I and VP-16, similar 
to the wild-type H1299 cells (Figure 3.23A). This suggested that the p53-ERTM fusion 
plasmid per se had no influence on the inhibitory effect of the compounds.  
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Figure 3.27: Influence of compound L and L-I on H1299 (MS48) 
Lung cancer cells H1299 (MS48), which were transfected with a p53-ERTM fusion plasmid, were treated with 
different concentrations of compound L or L-I alone (dark gray bar) or in combination with 1 µM VP-16 (light 
gray bar). SubG1 phase was measured by FACS analysis and displayed as % cell death. Values correspond to the 
average cell death of three independent experiments ± standard deviation. 
 
In the next experiments, 100 nM tamoxifen (subsequently designated “+T” in the text) was 
added simultaneously with the inhibitors L or L-I and VP-16 to the cells, and cells were 
incubated for 48 h.  
In the case of compound L, the treatment with 20 µM of the inhibitor alone led to an increase 
of apoptosis from approximately 7 % of untreated H1299 (MS48) +T cells to approximately 
15 %. However, this is comparable to the H1299 (MS48) cells where p53 is not activated, 
suggesting that the induced apoptosis by L alone was not p53-dependent. The combined 
treatment of the H1299 (MS48) +T cells with compound L and VP-16 induced a slight 
additional increase of apoptosis from approximately 17 % of untreated cells to 22 % at the 
highest concentration of L, though this difference was not statistically significant. These 
results are also comparable to the H1299 (MS48) cells without p53 induction, and this further 
indicated that the additional induced apoptosis by compound L was not p53-dependent.  
In the case of compound L-I, we observed that apoptosis increased from approximately 7 % 
of untreated H1299 (MS48) +T cells to 25 % of H1299 (MS48) +T cells that were treated 
with 20 µM of L-I alone. This effect was not observed in H1299 wild-type cells (Figure 
3.23B), where L-I treatment induced 10 % cell death at 20 µM, suggesting that the p53 
induction sensitizes cells to apoptosis by L-I. However, the combined treatment of H1299 
(MS48) +T cells with L-I and VP-16 led to a measurable additional increase of apoptosis 
from approximately 20 % of untreated cells to 30 % at the highest concentration of L-I. In the 
A549 cells we observed an additional increase from approximately 4 % of untreated cells to 
24 % at the highest concentration of L-I (Figure 3.23B), displaying a stronger effect of L-I in 
A549 cells than in the H1299 (MS48) +T cells. This indicated that the activation of p53 did 
not enhance L-I mediated apoptosis in VP-16-sensitized cells. Altogether, these results 
suggested that the inhibitor-mediated apoptosis by L-I might be partially p53-dependent. As 
0
5
10
15
20
25
30
35
40
45
50
0 0,5 1 5 10 20
H1299 (MS48)
compound L (!M)
%
 c
e
ll 
d
e
a
th
 
0 0,5 1 5 10 20
0 M
VP-16
1 M
VP-16%
 c
e
ll 
d
e
a
th
 
compound L-I (!M)
0
5
10
15
20
25
30
35
40
45
50
H1299 (MS48)
0 M
VP-16
1 M
VP-16
0 0,5 1 5 10
compound L-I (!M)
20
%
 c
e
ll 
d
e
a
th
 
0
5
10
15
20
25
30
35
40
45
50
0
5
10
15
20
25
30
35
40
45
50
H1299 (MS48) + tamoxifen
0 0,5 1 5 10 20
compound L (!M)
%
 c
e
ll 
d
e
a
th
 
H1299 (MS48) + tamoxifen
Results 
 70 
mentioned above, SirT2 inhibits a broad range of substrates, and the results indicated that 
more targets than p53 might be affected by the inhibitors L, L-I as well as H and may also be 
responsible for the in vivo effects. 
 
 
Figure 3.28: Influence of compound L and L-I on H1299 (MS48) after tamoxifen treatment 
Lung cancer cells H1299 (MS48), which were transfected with a p53 plasmid, were treated with different 
concentrations of compound L or L-I alone (dark gray bar) or in combination with 1 µM VP-16 (light gray bar). 
Additionally, the cells were treated with tamoxifen to activate the p53 protein. SubG1 phase was measured by 
FACS analysis and displayed as % cell death. Values correspond to the average cell death of three independent 
experiments ± standard deviation. 
 
3.3.4 Inhibitors did not change the acetylation level of sirtuin targets  
To determine whether SirT1 or SirT2 were directly inhibited in vivo by the compounds L, L-I 
as well as H and to test which target of both enzymes were affected, we sought to analyze the 
acetylation level of p53, a target of both enzymes, as well as of α-tubulin, a substrate of 
SirT2. To determine the acetylation level of p53, the A549 cell line was treated with 
compound H, L or L-I alone and in combination with VP-16, similar to the experiments for 
the analysis of apoptosis. The p53 protein is often found in latent forms, and the levels of p53 
protein are very low in unstressed cells, mainly due to degradation mechanisms (Luo et al. 
2001). Therefore, we treated the cells with VP-16 in order to induce stress. Subsequently, 
whole cell protein was isolated and subjected to SDS-PAGE gel and Western blots. The 
acetylation level of p53 was determined by Western blotting with an α-Acp53 (K382) antibody 
(Figure 3.29). As expected, treatment of cells with VP-16 led to an increase in total p53 
levels as well as an increase in acetylated p53. This is in agreement with published data of 
(Luo et al. 2001), that after VP-16 treatment, cells were stressed and the p53 protein level was 
increased. The potent SirT1 inhibitor, Ex527 (Napper et al. 2005), was used as control, but it 
produced at most a marginal increase of the p53 acetylation signal (Lane 4) on VP-16-induced 
p53. The inhibitors H, L as well as L-I identified in this study were also not able to increase 
the acetylation level of p53 that was induced by VP-16 treatment. On the contrary, p53 
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induction per se as well as acetylation, especially after treatment with H and L, was reduced 
compared to VP-16 treatment alone, for reasons that are not clear.  
 
Figure 3.29: No additional increase of the p53 acetylation signal after inhibitor treatments 
The A549 cells were treated 10 µM of each compound alone and in combination with 1 µM VP-16. The 
acetylation level of p53 protein was determined by Western blotting with α-Acp53 (K382) antibody. For the 
detection of cellular p53 level the α-p53 antibody was used. An unspecific band of the α-p53 antibody (*) was 
used as loading control. The p53 level was quantified using the program ImageJ, whereby the p53 level of 
untreated cells was set to 1.0. 
 
The acetylation level of α-tubulin was determined by Western blotting with α-Ac-tubulin 
(K40) antibody. As shown in Figure 3.30, no acetylation signal of α-tubulin could be 
observed after inhibitor treatment, except for the cells that were treated with trichostin A 
(TSA). TSA, a potent HDAC inhibitor, inhibits HDAC6 that is also known to deacetylate α-
tubulin and this led to a strong increase of the α-tubulin acetylation signal. It is proposed that 
HDAC6 and SirT2 have a shared role in deacetylating α-tubulin (Heltweg et al. 2006), 
however an acetylation signal after treatment with L or L-I could not be observed.  
 
Figure 3.30: No acetylation signal of α-tubulin after treatment with L or L-I 
The A549 cells were treated with 10 µM of L or L-I alone or in combination with 1 µM VP-16. The acetylation 
level of tubulin was determined by Western blotting with α-Ac-tubulin (K40) antibody. The level of whole 
tubulin was detected by α-tubulin antibody and used as loading control. 
 
These results indicated that the in vivo influence of the inhibitors H, L as well as L-I is 
insufficient to observe an increase of the acetylation signal on p53 and α-tubulin, even though 
they are in vitro inhibitors of SirT1 and SirT2, respectively. This furthermore indicated that 
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their in vivo effect may result from inhibition of deacetylation of other target proteins, or from 
sirtuin-independent cellular effects.  
 
3.3.5 ySir2 inhibitors did not inhibit silencing in yeast  
Yeast Sir2 is required for silencing at the silent mating-type loci (HMR and HML), the 
telomeres and at rDNA in S. cerevisiae. Splitomicin is a potent ySir2 inhibitor with an IC50 
value of 60 µM in vitro and is able to inhibit ySir2-dependent silencing at all three loci in 
yeast (Bedalov et al. 2001). Since the inhibitors identified in this study showed a similar 
degree of in vitro inhibition of ySir2 as splitomicin, we performed HM silencing assays to 
determine whether these compounds affected ySir2 in vivo. As described in 1.4.1, haploid 
yeast cells contain one allele of MAT (a or α), which determines their mating-type, and two 
additional copies of the mating-type information (HML and HMR) that are silenced. Cells 
expressing α information can only mate with MATa cells, which produces MATa/α diploid 
cells. Here, we used a highly sensitive silencing assay to probe for Sir2 inhibition. For this 
purpose, a mataΔp strain carrying a modified HMR cassette was used (ROY1). This HMR 
allele (HMR-ssα) carries α instead of a information and is governed by a synthetic HMR 
silencer (ss) (Kamakaka and Rine 1998). Derepression of HMR, for instance by Sir2 
inhibition, results in expression of α information, which in the mataΔp background leads to 
an α mating-type and thus to mating with a MATa tester strain. To test for Sir2 inhibition, 
logarithmically growing cells of both strains were plated on YM plate to a final OD600 of 0.5 
of each strain. Subsequently, paper discs with 2 µl of DMSO or different concentrations of the 
inhibitor (all except for B, C, E, K and M) were placed onto the agar, and the plate was 
incubated at 30 °C for 2 days. Auxotrophic markers were selected such that diploid cells can 
grow on this medium. The yield of diploid cells was taken as indicator for HMR silencing, 
and 2 µl of splitomicin (10 mM) was used as positive control. Splitomicin inhibits ySir2 in 
vivo and thereby the ROY1 strain becomes an α−mater, which is able to mate with the 
mating-type tester strain MATa, as can be seen as the growth of diploids around the 
splitomicin filter disc. Figure 3.31 shows an example for the results of all inhibitors that were 
tested. None of them showed an inhibition of the ySir2-mediated HMR silencing, suggesting 
that the inhibitors did not inhibit ySir2 in vivo.  
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Figure 3.31: ySir2 inhibitors had no influence on HMR silencing 
A mataΔp HMR-ssα (ROY1) as well as the mating-type tester MATa were plated on a YM plate (right site). 
Paper disc with 2 µl of different concentrations of ySir2 inhibitor were placed onto the agar as indicated by the 
scheme on the left site. 2 µl of DMSO as well as 2 µl of splitomicin (10 mM) were used as positive control. 
 
3.4 Validation and characterization of potential sirtuin activators  
 
The validation and characterization of the activators that were identified by the high 
throughput screen of the ChemBioNet library was performed by Louisa Hill during her master 
thesis (Hill 2012).  
 
Figure 3.32: Chemical structures of potential SirT1 activators 
 
The validation of the activators with the MAL deacetylation assay showed that of 12 
activators, seven (Figure 3.32) induced a potent activation of SirT1 activity (Figure 3.33). 
The activators 1, 2, as well as 3 showed the strongest activation of SirT1, whereas the 
compounds 4 to 7 showed a moderate activation of SirT1.  
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Figure 3.33: Identification of SirT1 activators 
The influence of potential SirT1 activators (1-7) was determined by MAL deacetylation assay. The control 
reaction containing DMSO was set to 100 %. IC50 values and curve fitting were performed using GraphPad. 
Values correspond to average enzyme activity of a 3-fold measurement ± standard deviation. The MAL 
deacetylation assays were performed by Louisa Hill (Hill 2012). 
 
Furthermore, the effect of these potential activators was measured by the HPLC-based p53 
deacetylation assay, and this showed that none of them was able to enhance the activity of 
SirT1 (Hill 2012). As opposed to this, surprisingly, compound 1 (Figure 3.32) strongly 
inhibited SirT1 activity in the HPLC-based p53 deacetylation assay. This suggested that the 
influence of a small molecule on the SirT1 activity depends on the environment of the 
deacetylation substrate.  
Furthermore, the effect of these potential activators was measured with the SirT1 truncations 
(see 3.2.1) and with ySir2 in the MAL deacetylation assay.  
  
Figure 3.34: Influence of compound 1 on SirT1 truncations 
The influence of compound 1 on SirT1 truncations was determined by MAL deacetylation assay. The control 
reaction containing DMSO was set to 100 %. IC50 values and curve fitting were performed using GraphPad. 
Values correspond to average enzyme activity of a 3-fold determination ± standard deviation. The MAL 
deacetylation assays were performed by Louisa Hill (Hill 2012). 
 
Surprisingly, the shorter constructs SirT1_D, SirT1_E as well as SirT1_F were inhibited by 
compound 1 (Figure 3.34). These results indicated that the N-terminal region of SirT1 had an 
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influence of the enhancement of the SirT1 activity. Furthermore, compound 1 may be a more 
potent inhibitor when SirT enzymes with a shortening N-terminal region were used.  
Based on these results from Louisa Hill, we measured the effect of compound 1 on the 
activity of ySir2 as well as of SirT2 in the MAL deacetylation assay, because both have a 
relatively short N-terminal region in comparison to SirT1. Notably, compound 1 inhibited 
both enzymes in the MAL-deacetylation assay (Figure 3.35A) with an IC50 value of 58.2 µM 
for ySir2 and 88.2 µM for SirT2. Additionally, SirT2 was also inhibited in the HPLC-based 
p53 deacetylation assay (Figure 3.35B), where a lower concentration was required to inhibit 
50 % of SirT2 activity than the IC50 value of the MAL deacetylation assay.  
      
Figure 3.35: Inhibitory effect of compound 1 on SirT2 and yeast Sir2 
(A) The inhibitory effect of compound 1 on SirT2 and yeast Sir2 activity was measured by fluorescence-based 
assay. IC50 curve fitting was performed using GraphPad. (B) The inhibitory effect of 50 µM, 100 µM and 
200 µM of compound 1 on SirT2 was analyzed by HPLC-based assay and displayed as % of SirT2 activity. In 
both assays (A and B) the control reaction containing DMSO was set to 100 %. Values correspond to the average 
enzyme activity of three independent experiments ± standard deviation.  
 
These results suggested that compound 1 might be a more potent inhibitor of SirT enzymes 
with a short N-terminal region independently of the deacetylation substrate.  
The IC50 value of compound 1 (58 µM) for ySir2 was comparable with the IC50 value of 
splitomicin (60 µM; (Bedalov et al. 2001)). For this reason we performed HM silencing assay 
as described in 3.3.5. However no inhibition of ySir2-dependent HM silencing was observed. 
This indicated that compound 1 was not able to inhibit ySir2 in vivo, or its in vivo influence 
was insufficient to observe an effect.  
 
 
 
A B 
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4. Discussion 
 
Sirtuin family members, homologs of the Silent Information Regulator Two (Sir2) protein 
from yeast, are best known as NAD+-dependent deacetylases, and some family members 
possess ribosyltransferase, demalonylase and desuccinylase activities (Frye 1999; Landry et 
al. 2000; Du et al. 2011). They are conserved from bacteria to humans and target both 
histones and a broad range of non-histone proteins. The best and most extensively studied 
sirtuin is SirT1 that deacetylates a number of important transcription factors such as p53, 
FOXO family members, PGC1-α and many more. Therefore, SirT1 is involved in a variety of 
biological processes including cell survival, apoptosis, cancer development and stress 
resistance (reviewed in (McGuinness et al. 2011)). Based on these roles of sirtuins, small 
molecules that influence the activity of sirtuins are deemed promising candidates for therapies 
of a variety of different diseases. So far, a variety of modulators exist that inhibit or activate 
sirtuins, but most of them have a low bioavailability, interact with multiple targets or have a 
high IC50 value. Furthermore, many details of the sirtuin reaction mechanism and regulation 
are still unclear. The SirT5/suramin complex has provided important insights into the 
inhibitory mechanism of suramin (Schuetz et al. 2007), but this to date is the only sirtuin 
structure bound to an inhibitor, which limits our knowledge about sirtuins, especially 
considering that many other sirtuin inhibitors with greater selectivity have been identified 
(Yuan and Marmorstein 2012). Additionally, the effect of putative activators of sirtuins 
(Howitz et al. 2003; Milne et al. 2007) have been shown to be substrate and assay dependent 
(Borra et al. 2004; Kaeberlein et al. 2005; Beher et al. 2009; Pacholec et al. 2010). In this 
study, we have identified inhibitors of SirT1 as well as SirT2 that can be developed further for 
anticancer therapy.  
 
4.1 Identification of SirT1 inhibitors  
 
For the identification of novel small molecules that influence the deacetylase activity of 
sirtuins, in particular of SirT1, we established a high-throughput fluorescence-based 
deacetylation assay as described in (Heltweg et al. 2003). As a substrate, we used a acetylated 
lysine that is coupled with a fluorophore (MAL (Hoffmann et al. 1999)). The screen of a 
small natural compound library (purchased from BIOMOL) resulted in four inhibitors and 
three activators of SirT1. The inhibitors rottlerin, shikonin, dihydrotanshinone as well as 
cryptotanshinone showed IC50 values in the micro-molar range, and they have not been 
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identified as sirtuin inhibitors so far. However, rottlerin is a well-known protein kinase 
inhibitor C (PKC; (Gschwendt et al. 1994)). Since SirT1 requires NAD+ as a cofactor, which 
shares structural features with ATP, the cofactor of kinases, it is therefore possible that 
rottlerin inhibits SirT1 via competitive inhibition in the NAD+ binding pocket. This 
furthermore indicated that rottlerin may have further cellular targets and thus likely has 
pleiotropic effects in the cell. It therefore was not further investigated here. 
Shikonin is isolated from the plant Lithospermum (purple gromwell) and is used in Chinese 
herbal medicine (Chen et al. 2003). It is known to inhibit cell growth and induces apoptosis 
that is mediated by activation of p53 (Wu et al. 2004a; Wu et al. 2004b). One therefore can 
speculate that shikonin inhibits SirT1, resulting in increased p53 acetylation, which becomes 
active in response to stress. However, the chemical structure of shikonin (Figure 3.4) contains 
a reactive para-quinone group (Prof. M. Kaiser, personal communication), and we therefore 
speculate that shikonin interacts with multiple targets and does not inhibit SirT1 specifically. 
Our in vivo experiments indicated that shikonin has a high cellular toxicity, since a 
concentration of 1 µM of shikonin induced nearly 100 % cell death.  
The inhibitors dihydrotanshinone and cryptotanshinone are derived from the plant Salvia 
miltiorrhiza (red sage) and are also used in Chinese herbal medicine (Lee et al. 1999). 
Cryptotanshinone is a potent STAT3 (signal transducer and activator of transcription 3) 
inhibitor (Shin et al. 2009), whereas dihydrotanshinone inhibits cell proliferation and tumour 
growth of breast cancer (Tsai et al. 2007). Similar to shikonin, both contain a reactive quinone 
in their chemical structure (Figure 3.4) and therefore may be unspecific inhibitors, which 
might explain their high toxicity in the cell culture experiments.  
The SirT1 activators quercetin, luteolin and kaempferol that were identified in the BIOMOL 
compound library are already known as sirtuin activators (Howitz et al. 2003). The fact that 
we were able to identify them in our screen confirmed the potential of identifying novel 
activators in the MAL deacetylase assay. Next, we performed a high-throughput screen of the 
ChemBioNet library. This screen resulted in several potential activators as well as inhibitors 
of SirT1. After subsequent validation steps, we arrived at 14 potential inhibitors and 12 
activators. During this study, we concentrated on characterization of the inhibitors. The 
activating effect of the 12 putative SirT1 activators was characterized by Louisa Hill during 
her master thesis (overview in 3.5), and a number of follow-up experiments are presented in 
this thesis.  
The inhibitory effect of 13 out of 14 inhibitors was confirmed by the MAL deacetylation 
assay. All of them showed a concentration-dependent inhibition of SirT1, and their IC50 
values vary from 2.4 µM (compound A) to 173.2 µM (compound M). Several studies have 
Discussion 
 78 
shown that the fluorophore attached on the substrate influences the activity of sirtuins in the 
fluorescence-based assays (Kaeberlein et al. 2005; Beher et al. 2009), though this has mainly 
been described for the putative activators of sirtuins. Here, we established a deacetylase 
activity assay that is independent of the presence of the fluorophore in order to verify the 
inhibitory effect of the compounds. For this assay we used an acetylated p53-derived peptide 
(aa 368 -386 of p53; K382Ac) without fluorophore. Several of the inhibitors were able to 
inhibit SirT1-dependent p53 deacetylation, but their effect was less pronounced than in the 
MAL deacetylation assay. Suramin, the well-known SirT1 inhibitor that showed an IC50 value 
of 4.7 µM in the MAL deacetylation assay, inhibited SirT1-dependent p53 deacetylation to 
50 % at 20 µM. Also the inhibitors shikonin, dihydrotanshinone as well as cryptotanshinone 
with an IC50 value of 1.6 µM and 3.4 µM in the MAL deacetylation assay, inhibited the p53 
deacetylation to 50 % - 60 % at a concentration of 20 µM. The compounds A – D had IC50 
values lower than 10 µM for MAL deacetylation, but except for compound B, they failed to 
inhibit p53 deacetylation to 50 % at a concentration of 50 µM. Compound B inhibited SirT1 
activity to 50 % in this p53 deacetylation assay at 20 µM and that had an effect comparable to 
suramin. All the other inhibitors, except for compound F, failed to inhibit SirT1 activity to 
50 % at a concentration of 50 µM. F showed inhibition of 50 % SirT1 activity at 50 µM, 
although it had an IC50 value of 27.7 µM in the MAL deacetylation assay. The poor inhibition 
of SirT1-dependent p53 deacetylation by the inhibitors in comparison to the MAL 
deacetylation could be due to the different substrates in the two assays. SirT1 has poor affinity 
for the substrate MAL, which is in contrast to the p53 peptide, which is the preferred substrate 
(Heltweg et al. 2003; Pan et al. 2012). For this reason, it is conceivable that a higher 
concentration of inhibitor is necessary to inhibit p53 deacetylation in comparison to the MAL 
deacetylation. Furthermore, Kaeberlein et al. showed that the fluorophore on the substrate 
decreases the binding affinity of SirT1 to this substrate (Kaeberlein et al. 2005), which is in 
agreement with our results.  
Together, in comparison to the known inhibitor cambinol that induces a chemosensitization of 
cancer cells and has an IC50 value of 56 µM for SirT1, several inhibitors identified here are 
more potent SirT1 inhibitors. However, in view of the known inhibitors Ex527, tenovin-6 as 
well as HR73, a splitomicin derivate, which have IC50 values lower than 10 µM for SirT1, the 
compounds identified here are not the best SirT1 inhibitors.  
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4.2 The inhibitory activity of sirtuin inhibitors is influenced by the N-
terminal region of sirtuins  
 
A sequence alignment of sirtuins shows that they share a highly conserved catalytic core 
domain, but that their N- and C-terminal regions vary in length and sequence. These regions 
play important roles in acetyl-lysine and NAD+ binding (Zhao et al. 2003a) and may perform 
protein-specific functions and possibly also confer substrate specificity (Sanders et al. 2010). 
Marmorstein et al. showed that the amino acids of the p53 peptide flanking the acetyl-lysine 
(K382) mainly interact with the Sir2Tm (from bacteria Thermotoga maritime) enzyme, which 
includes hydrogen bonds with N165 and G163 as well as van der Waals interaction with F162 
and V193, and this has significant effect on the substrate binding affinity (Yuan and 
Marmorstein 2012). Here, we tested the MAL deacetylase activity of other sirtuin family 
members (SirT2 to SirT7) with the exception of SirT4 that has no obvious deacetylase activity 
(Haigis et al. 2006) and only SirT2 and SirT3 were able to deacetylate MAL. This may be in 
agreement with published data of (Yuan and Marmorstein 2012), because the MAL substrate 
has no amino acids that flank the acetyl-lysine and interact with the sirtuin enzymes, therefore 
the substrate binding affinity is very low and the substrate is not recognized by the other 
sirtuin members. In support of this, for SirT6 and SirT7 the only known substrates are 
histones (Michishita et al. 2008; Barber et al. 2012), and SirT5 has a weak deacetylase 
activity (Du et al. 2011).  
Similar to (Milne et al. 2007), who show that the N-terminal region is required for SirT1 
activation by resveratrol, we generated SirT1 constructs that are truncated in the N-terminus. 
In agreement with the published data of Milne et al., we could show that resveratrol was able 
to activate the constructs with an extended N-terminus SirT1_A (156-664) and SirT1_B (172-
664), but not the shorter constructs. Suramin inhibited all SirT1 truncations independently of 
the presence or the length of the N-terminal region, which indicates that suramin does not 
interact with the N-terminus. This is consistent with the observation of Schuetz et al. that the 
trisulfonyl naphthyl group of suramin binds to the NAD+ binding pockets B and C, and that 
several of the benzene rings bind in the peptide binding site (Schuetz et al. 2007). 
Our analysis showed that the N-terminal region of SirT1 has an influence of the inhibitory 
effect of compound D. The inhibitor D showed a strong inhibition of more than 50 % of the 
deacetylase activity only of full-length SirT1 as well as the longer SirT1 truncations SirT1_A 
(156-664) and SirT1_B (172-664) at a concentration of 50 µM. The shorter constructs 
SirT1_D (225-664) and SirT1_E (230-664) were not inhibited by compound D. These results 
indicate that D might interact with the first 225 amino acids of the N-terminal region of SirT1. 
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However, compound D also inhibited the activity of the shortest construct SirT1_F (235-664) 
to approximately 50 % at 50 µM, which was unexpected. However, this could be due to the 
reduced deacetylase activity of SirT1_F compared to the full-length SirT1 and the other SirT1 
truncations, and therefore a lower inhibitor concentration might be sufficient to inhibit this 
construct. Furthermore, SirT2 was also inhibited by D to approximately 20 % at a 
concentration of 50 µM, similar to the inhibition of full length SirT1. This suggests that 
compound D might interact with a specific region in the N-terminal region of SirT1 and 
SirT2. In support of this theory, SirT3, whose active deacetylase form has no N-terminal 
region, was not inhibited by D. The ySir2 was also inhibited by compound D, but to a lesser 
extent than SirT1 and SirT2. In view of the fact that SirT1 is the closest homolog of ySir2, 
one could hypothesize that compound D inhibits ySir2 and SirT1 equally, but this was not the 
case. However, considering the sequence alignment of SirT1 versus SirT2 and ySir2 (Figure 
4.1), SirT1 and SirT2 contain conserved residues in the N-terminal region that are not present 
in the N-terminus of ySir2. These residues are the amino acids P184, G195 D204, E208, E214, L220, 
L228, S229, D239 and E244 of SirT1 (marked in bold in Figure 4.1), and perhaps one or more of 
theses residues are responsible for the interaction with compound D. To validate this 
hypothesis, the generation of alanine mutants of these specific residues could be useful. The 
enzyme with a mutation of the respective amino acid that is responsible for the interaction 
with compound D should not be inhibited by D any more.  
 
 151                                                200 
SirT1 EIITNGFHSC ESDEEDRASH ASSSDWTPRP RIGPYTFVQQ HLMIGTDPRT 
SirT2 .......... .......... .......... MAEPDPSHPL ETQAGKVQEA 
Sir2 KFLDTYLPED LNSLYIYYLI KLLGFEVKDQ ALIGTINSIV HINSQERVQD 
Consensus .......... .......... .......... raePdpfhqq elqaGkdqra 
 
 201                                                250 
SirT1 ILKDLLPET. IPPPELDDMT LWQIVINILS EPPKRKKRKD INTIEDAVKL 
SirT2 QDSDSDSEGG AAGGEADMDF LRNLFSQTLS LGSQKERLLD ELTLEGVARY 
Sir2 LGSAISVTNV EDPLAKKQTV RL.IKDLQRA INKVLCTRLR LSNFFTIDHF 
Consensus qdkDldpEg. aaggEaDddf Lr#ifi#iLS egpqrerrlD enTiEdaarl 
 
Figure 4.1 Sequence alignments of SirT1 vs. SirT2 and ySir2 
Alignment of the N-terminal region of SirT1 vs. SirT2 and ySir2 for comparison of specific residues (letters are 
marked in bold face). Catalytic core domain is located within amino acids 240 and 510 of SirT1. Alignments 
were generated using the webpage Multalin (http://multalin.toulouse.inra.fr/multalin/multalin.html). 
 
The compounds C, F, G, H, I and M showed the strongest inhibition with the shortest 
construct SirT1_F that has 9 aa N-terminal to the core domain. However, as mentioned above, 
this could be due to the lower deacetylase activity of SirT1_F compared to the full-length 
SirT1. Considering the inhibition of full-length SirT1, SirT1_A, SirT1_B, SirT1_D and 
SirT1_E by these inhibitors, thus suggests that the N-terminal region has only a slight effect 
on the inhibition in comparison to compound D. The compounds C, F, G, H and I still 
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inhibited the shorter constructs by approximately 40 % - 50 % and compound M by 
approximately 30 % - 40 % at 50 µM. In support of this, compound H and M also inhibited 
ySir2, SirT2 as well as SirT3 by 20 % or more at 50 µM, suggesting that these both 
compounds also interact with the core domain that is conserved in all sirtuins. In contrast to 
this, compound C and F did not affect ySir2, SirT2 or SirT3, which suggested that next to the 
core domain and the N-terminal region, an additional factor has an influence on the inhibitory 
effect. This raised the question whether the C-terminal region of sirtuins, which varies among 
the sirtuin family members, also plays a role for the inhibitory effect of these compounds. The 
C-terminal region of SirT1 may potentiate the deacetylase activity by an intra-molecular 
mechanism, it interacts with the catalytic core domain to form a SirT1 holoenzyme (Pan et al. 
2012). Perhaps, the inhibitors disrupt the interaction between the SirT1 core domain and the 
C-terminal region. This could also be an explanation for the inhibitory effect of the 
compounds shikonin, dihydrotanshinone, cryptotanshinone as well as compound A and B that 
showed a specific inhibition of SirT1 that is independent of the presence of the N-terminus. In 
agreement with this theory, the compounds showed no or a rather weak inhibition of SirT2 
and SirT3. To investigate whether some of the inhibitors identified in this study interact with 
the C-terminal region of SirT1, the generation of SirT1 truncations at the C-terminus would 
be required. 
 
4.3 Compound L is a potent inhibitor of SirT2 
 
During the experiments with other sirtuin family members, we observed that compound L 
inhibited SirT2 to a greater extent than SirT1. We performed an IC50 curve and determined a 
6-fold lower IC50 value for SirT2 (18.5 µM) in comparison to SirT1 (118.4 µM) in the MAL 
deacetylation assay. Additionally, compound L showed a stronger inhibition of SirT2-
dependent p53 deacetylation as measured by the HPLC-based assay in comparison to SirT1. 
At a concentration of 50 µM, compound L inhibited SirT2 activity to approximately 20 %, 
whereas SirT1 activity was inhibited to 10 %. These results indicate that compound L is a 
potent SirT2 inhibitor independently of the substrate. These results show that compound L 
displays some degree of selectivity for SirT2 inhibition. The known inhibitor AC-93253 
shows potent inhibition of SirT2 activity with an IC50 value of 6.0 µM, however it also 
inhibits SirT1 with an IC50 value of 43.5 µM (Zhang et al. 2009). 
In an effort to determine which element of the chemical structure of compound L is important 
for its inhibitory effect, we obtained derivates of L and measured their inhibition of 
deacetylase activity by the MAL deacetylation assay. All derivates are structurally similar to 
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each other, but have different substituents attached at the carboxamidegroup. One of these 
derivates, compound L-I, showed a stronger inhibition of SirT2-dependent MAL 
deacetylation in comparison to L. The IC50 value was reduced to 3.8 µM. In the p53 
deacetylation assay, L-I inhibited SirT2 activity to approximately 20 % at a concentration of 
20 µM. These results suggest that the addition of the heterocyclic pyridine increases the 
binding affinity of compound L to SirT2, probably through additional π-π interactions. In 
contrast to this, the ether group of compound L-II had no obvious influence on the inhibitory 
effect. L-II inhibited SirT2 deacetylase activity to a similar extent as compound L. The 
compounds L-III and L-IV showed a weaker or no inhibition of SirT2-dependent MAL 
deacetylation. This suggests that the addition of an anisole group, as is the case for L-III, or a 
methyl benzoate group, as is the case for L-IV, decreased the binding affinity for SirT2. Both 
substituents are unpolar groups and probably led to a decrease in the interaction between the 
inhibitor and SirT2.  
 
4.4 In vivo effect of Sirtuin inhibitors  
 
Since our biochemical results indicated that we had identified sirtuin inhibitors, we sought to 
determine whether they inhibited sirtuins in vivo in order to assess the anticancer potential of 
these compounds. For this purpose, we treated the human lung cancer line A549 with 
different concentrations of the identified inhibitors A to M as well as shikonin, 
dihydrotanshione and cryptotanshinone and measured apoptotic cells by FACS analysis. The 
three inhibitors shikonin, dihydrotanshinone and cryptotanshinone showed a strong increase 
of cell death at low concentrations of 1-2 µM. This suggests a high toxicity of these 
compounds, which may be related to the reactive quinone in their chemical structure. Thus, 
these compounds probably interact with multiple targets in the cell and not only inhibit SirT1 
in vivo.  
Of the other compounds, B, C, F, H, L as well as L-I caused a moderate increase of apoptosis 
at higher concentrations, indicating that they had an effect on the cells. To gain more insight 
into the in vivo effect of these inhibitors, the A549 cells were treated with these six 
compounds in combination with the chemotherapeutic agent etoposide (VP-16). Etoposide 
forms a ternary complex with DNA and the topoisomerase II enzyme, prevents re-ligation of 
the DNA strands and therefore causes DNA strand breaks (Hande 1998). Cancer cells divide 
more rapidly than normal cells, and therefore cancer cells should be more affected by 
etoposide, and this promotes apoptosis of the cancer cells. However, most of the cancer forms 
are resistant against such chemotherapeutic agents. The tumor suppressor p53 is known to 
Discussion 
 83 
exert anti-proliferative effects, including growth arrest, apoptosis and cell senescence in 
response to various types of stress (Levine 1997; Prives and Hall 1999). Luo et al. showed 
that SirT1 promotes cell survival in response to DNA damage by inhibiting p53-dependent 
apoptosis (Luo et al. 2001). Several cancer forms including lung cancer cells show increased 
levels of SirT1 protein (Fraga and Esteller 2007; Stunkel et al. 2007) and this might be the 
reason for the resistance of cancer cells against chemotherapeutic agents. This suggests that 
the combination with DNA damaging agents and SirT inhibitors may have synergistic effects 
in cancer therapy. In this study, we observed that A549 cells treated with VP-16 alone showed 
only a slight increase of cell death in comparison to untreated cells, consistent with the idea 
that they are resistant to such agents. After the treatment of A549 cells with the six inhibitors 
in combination with VP-16, the inhibitors H, L as well as L-I showed an additional increase 
of apoptosis, which is in line with published data of the expected effect of SirT1 inhibition 
(Hajji et al. 2010). In this paper, the human lung carcinoma cell line H157 was treated with 
1 µM Ex527, a potent SirT1 inhibitor (Napper et al. 2005), in combination with VP-16 and 
this led to an increase of cell death by 20 % in comparison to the treatment with the SirT1 
inhibitor alone. Furthermore, siRNA directed against SirT1 in H157 cells led to an increase of 
apoptosis by approximately 40 % after VP-16 treatment compared to the control siRNA (Hajji 
et al. 2010). SirT2 down-regulation using siRNA leads to a strong increase of apoptosis in 
cancer cells such as HeLa, but not in normal cells, which is caused by p53 accumulation (Li et 
al. 2011). Compound H showed a slight additional increase of apoptotic cells at low 
concentrations up to 5 µM in combination with VP-16. Compound L as well as L-I induced 
an additional increase of apoptosis by approximately 10 % at a concentration of 20 µM. 
Compared to the results of the inhibitor Ex527 (Hajji et al. 2010), our inhibitors showed a 
weaker effect, however Ex527 has a IC50 value of 0.098 µM for SirT1, so it is a more potent 
in vitro inhibitor than the compounds described here.  
The inhibitors L as well as L-I were selective for SirT2 with IC50 values of 18.4 µM (L) and 
3.8 µM (L-I), whereas compound H inhibited SirT1 with an IC50 value of 31.5 µM. Both 
enzymes SirT1 and SirT2 are known to deacetylate the tumor suppressor p53, the histone 
H4K16 and FOXO family members (reviewed in (McGuinness et al. 2011)). Additionally, 
SirT2 also deacetylates lysine 40 of α-tubulin, functioning together with another tubulin 
deacetylase, HDAC6 (North et al. 2003; Inoue et al. 2007). Therefore, both are connected 
with multiple cellular processes such as cell cycle progression and cell death. To determine 
whether the inhibitor-mediated induced cell death was p53-dependent, the lung cancer cell 
line H1299, which carries a partial deletion of the p53 gene and does not express p53, was 
used. As for A549 cells, H1299 cells were treated with different concentrations of the 
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inhibitors alone and in combination with VP-16, and apoptotic cells were quantified. The 
treatment with compound H alone led to a stronger increase of cell death in H1299 cells in 
comparison to the cell death in A549 cells. The combined treatment with VP-16 reduced the 
cell death in H1299 cells to a similar degree as in A549 cells. This suggests that cell death 
mediated by compound H was not solely dependent on p53. We showed that compound H 
strongly reduced cell proliferation as well as viability of cancer cell lines in a dose dependent 
manner, which suggest that H may be a potent antiproliferative agent. However, we have no 
indication as to whether it directly inhibited SirT1 in vivo and which SirT1 target was 
affected. We were unable to detect an increase of p53 acetylation after inhibitor treatment. 
Perhaps compound H did not directly inhibit SirT1 in vivo, or the effect was not sufficient to 
observe a change of the p53 acetylation level. Furthermore, compound H showed a moderate 
SirT1 inhibition with an IC50 value of 31.5 µM in the MAL deacetylation assay, therefore the 
concentration of 10 µM in vivo might be not sufficient to induce an effect. Peck et al. were 
unable to detect an increased p53 acetylation level of human breast carcinoma cell line MCF-
7 that was treated with 50 µM Ex527 (Peck et al. 2010), although this compound is a more 
potent SirT1 inhibitor than compound H. In contrast, cambinol inhibits SirT1 and SirT2 with 
IC50 values of 56 µM and 59 µM and it is known to induce SirT1-dependent sensitization of 
the lung cancer cells H460 to etoposide as well as G2 cell cycle arrest, but not apoptosis. 
Furthermore, cambinol is able to increase the acetylation level of p53, Ku70 and FOXO3a 
after combined treatment with VP-16, but the cambinol-mediated chemosensitization is 
preserved in cells lacking each of these proteins, suggesting that none of these SirT1 targets 
are responsible for the cambinol-mediated sensitization to etoposide (Heltweg et al. 2006). In 
support of this, sirtinol induced senescence-like growth arrest in MCF-7 as well as 
p53-deficient H1299 cancer cells. Transfection of siRNA against SirT1 in H1299 as well as 
MCF-7 cells showed growth arrest that was comparable to sirtinol treatment, indicating a 
SirT1-dependent manner. Furthermore, neither the expression nor the acetylation of p53 was 
upregulated by sirtinol or siRNA directed against SirT1 in MCF-7 cells. The authors supposed 
that the senescence-like growth arrest by sirtinol was accompanied by impaired activation of 
mitogen-activated protein kinase (MAPK) pathways (Ota et al. 2006). These results suggest 
that the role of SirT1 during stress is complex and not always p53 dependent, the effects of its 
inhibition are still unclear and may be cell context-specific.  
For compound L as well as L-I, we observed a decrease in viability of the cancer cell lines 
after treatment. However, the H1299 cells showed a slightly better viability than A549 cells 
after treatment with L or L-I. In case of compound L, we observed that the cell proliferation 
of A549 cells was reduced more strongly than for H1299 cells. Although both cell lines may 
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have more differences than only the p53 protein expression, this could be an indication that 
the effect of compounds L and L-I may be p53-dependent. In support of this theory, the 
H1299 cells showed no additional increase of cell death after combined treatment with L or 
L-I and VP-16, which was in contrast to A549 cells. To further investigate this, we obtained 
H1299 (MS48) cells that were transfected with a tamoxifen-regulated p53 expression vector 
(Prof. M. Schuler, University Hospital Essen) and as expected, cell death in this cell line was 
increased upon activation of p53 by tamoxifen, but only after treatment with 20 µM of 
inhibitor L-I alone and in combination with VP-16. As mentioned above, we observed that L-I 
also reduced the cell proliferation and cell viability of H1299 cells, which suggested that not 
solely p53 is responsible for the inhibitor-mediated effect. Furthermore, both inhibitors also 
induced apoptosis of H1299 cells to approximately 10 %. To test the direct inhibition of SirT2 
by compound L or L-I in vivo, we performed western blot analysis, but we were unable to 
observe an increase of the acetylation level of p53 or α-tubulin. It is therefore unclear whether 
these inhibitors directly inhibited SirT2 in vivo, or whether they affect other cell components. 
Splitomicin derivates with IC50 values of approximately 1 µM for SirT2 are able to reduce 
cell proliferation of MCF-7 cells and to induce acetylation of α-tubulin. However, it is 
discussed that the acetylation of α-tubulin mostly controlled by HDAC6, because the level of 
tubulin hyperacetylation that can be reached by class I and II HDAC inhibitors (e. g. 
trichostin A) were never reached with any of the sirtuin inhibitors (Neugebauer et al. 2008). 
For this reason, it is possible that the effect of both inhibitors L and L-I is not sufficient to 
observe a change of the acetylation levels, as might be the case for compound H. Tenovin-6 
inhibits SirT2 activity to the same extent as tenovin-1 with an IC50 value of 10 µM, and both 
are able to increase the acetylation level of α-tubulin (to a lower extent than HDAC 
inhibitors) as well as p53 in H1299 cells transfected with p53 gene (Lain et al. 2008). 
Although the inhibitor L-I identified in this study might be a more potent SirT2 inhibitor than 
Tenovin-1 or -6 in vitro, we did not observed an increase of the acetylation level of α-tubulin 
or p53. This suggested that the inhibitor L-I and L did not directly inhibit SirT2 in vivo or that 
they interact with multiple targets. Furthermore, we have no indication whether the inhibitors 
were able to enter the cell, although the dose-dependent decrease of cell viability or 
proliferation might be an indication that they were able to enter the cell. Nonetheless, several 
further experiments will be necessary to determine their cell permeability, and to determine 
their in vivo targets. Based on the results that potent SirT1 inhibitors such as Ex527 also failed 
to increase the acetylation level of p53 (Peck et al. 2010) or that the cambinol-mediated 
chemosensitization is independent of p53, Ku70 and FOXO3a (Heltweg et al. 2006), it is 
likely that unknown sirtuin targets exist that affect cancer cell survival.  
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4.5 A SirT1 activator is an inhibitor of SirT2 and ySir2 
 
As mentioned earlier, the MAL deacetylation assay is controversial, because the fluorophore 
attached to the substrate influences the sirtuin activity. For this reason, the results of the 
putative activators of SirT1 identified in this study have to be interpreted with care. The 
validation and characterization of these compounds was performed by Louisa Hill during her 
master thesis (Hill 2012). She verified the activation of SirT1 by the compounds in the MAL 
deacetylation as well as in the HPLC-based p53 deacetylation assay. Similar to published data 
of resveratrol and other STACs (Kaeberlein et al. 2005; Beher et al. 2009), the putative 
activators failed to enhance the activity of SirT1 when the p53 substrate lacking a fluorophore 
was used. She also verified the activation by these compounds of the SirT1 truncations that 
were generated during this study. Only the longest constructs SirT1_A as well as SirT1_B 
could be activated by all compounds in the MAL deacetylation assay. The shorter constructs 
were not affected, and some compounds even inhibited their activity. One of these putative 
activators, compound 1 also inhibited the full-length SirT1 in the p53 deacetylation assay. 
This indicates that the effect of a modulator on sirtuin activity is strongly dependent on the 
molecular environment of the acetyl-lysine substrate residue.  
Based on these results, we performed further analysis of compound 1 in order to characterize 
its properties. The influence of compound 1 on other sirtuin members like ySir2 and SirT2 
was measured by the MAL deacetylation assay, and we observed that both were inhibited by 
compound 1 (IC50 for SirT2 88.2 µM and ySir2 58.0 µM). SirT2 activity was also strongly 
inhibited by compound 1 in the p53 deacetylation assay. At a concentration of 50 µM, 
compound 1 inhibited SirT2-dependent p53 deacetylation to approximately 50 %, which 
represents a greater inhibition of p53 deacetylation than MAL deacetylation. These results 
showed that we had identified a inhibitor of ySir2 and SirT2, even though the compound was 
originally identified as a potential SirT1 activator. To determine whether compound 1 affects 
SirT2 in vivo, we measured the acetylation level of α-tubulin after treatment, but we were 
unable to observe any differences. In view of the high IC50 value of SirT2, this result may not 
be surprising. Due to the concentration of the stock solution of compound 1 and the high 
volume of cell culture medium, the highest concentration that could be used was 10 µM and 
this was probably too low to efficiently affect SirT2 in vivo. Furthermore, it is unknown 
whether this compound was able to enter the cell and reach intracellular SirT2, because no 
effect on the cell could be observed. The IC50 value of ySir2 of 58.0 µM is comparable with 
the IC50 value of splitomicin for ySir2 (60 µM (Bedalov et al. 2001)). In view of the fact that 
splitomicin is able to inhibit ySir2-dependent silencing at telomeres, the silent mating-type 
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loci (HMR and HML), and at rDNA in S. cerevisiae (Bedalov et al. 2001), we tested the 
influence of compound 1 on HMR silencing in yeast. However, HMR silencing was not 
affected by compound 1. Possibly, this compound interacts with multiple targets in vivo, 
because of the reactive quinone derivates at each end of its chemical structure. For this reason 
it might not reach its actual target ySir2 or SirT2, or cell permeability. One possibility would 
be to identify derivatives of this compound with a less reactive structure that still display the 
inhibitory effect on sirtuins. To this end, it will be necessary to determine which structural 
elements are responsible for the inhibition, which could be performed with different derivates 
of compound 1 in the same manner as it was done in this study for compound L.  
 
4.6 Summary and Outlook 
 
In this study, we have identified several sirtuin inhibitors, compound H as a SirT1 inhibitor, 
and compound L as well as L-I as potent SirT2 inhibitors. We could show that all three have 
an antiproliferative potential, and in the case of compound L-I, we were able to show that the 
induced apoptosis might be partly p53-dependent. However we were not able to identify a 
sirtuin inhibitor that is more potent than all other known inhibitors.  
In future experiments this will need to be validated in order to verify the direct in vivo SirT2 
inhibition by compound L and L-I. Such experiments could be the analysis of the protein and 
mRNA expression of p53-downstream targets like p21 to determine whether these inhibitors 
activate p53 by SirT1 inhibition. However, several publications have shown that p53 is not 
always responsible for the sirtuin inhibitor-mediated effect; the actual target is mostly 
unknown (Heltweg et al. 2006; Peck et al. 2010). For this reason, target identification studies 
will be necessary. In view of the fact that SirT1 as well as SirT2 deacetylate a broad range of 
proteins, a genome-wide screen will be useful. Such screen could be a peptide array, where a 
number of different acetylated peptides are bound to a cellulose membrane and incubate with 
the sirtuin. Subsequently, the deacetylated peptides are detected by an antibody, which signal 
can be measured by a fluorescence-reader (Smith et al. 2011). 
In collaboration with chemists, the three potent inhibitors H, L as well as L-I could be further 
derivatized in order to obtain an IC50 value in the nano-molar range and to optimize their 
inhibitory effect in vivo. For this purpose, it would be useful to obtain information about their 
solubility, permeability through the cell membrane and also their metabolization in the cell.  
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5. Abstract 
 
Sirtuins (SirT1-7) are the human homologues of the NAD+-dependent histone deacetylase 
Sir2 from Saccharomyces cerevisiae (ySir2). Since the overexpression of Sir2 in yeast 
increases lifespan, the study of mammalian sirtuins has gained widespread interest. Each 
sirtuin is characterized by a conserved 275 amino-acid catalytic core domain as well as by 
unique additional N-terminal and/or C-terminal sequences of variable length. Sirtuins hold 
promise as potential drug targets for the treatment of a variety of conditions, including cancer, 
metabolic diseases, diabetes and aging. Although, a number of sirtuin inhibitors as well as 
activators are known, the inhibitory mechanism of sirtuins is still unknown. In this study, we 
sought to identify novel inhibitors of SirT1, and we assessed their in vivo potential as 
chemotherapeutic agents. For this purpose, we established a fluorescence-based deacetylation 
assay using methyl-aminocoumarin-acetyllysine (MAL) as a substrate that is suitable for 
high-throughput screening. Two compound libraries (500 and 18.000 compounds, 
respectively) were screened for SirT1-modulating activities, and we identified 14 potential 
inhibitors and 12 potential activators of SirT1. Of the inhibitors, 9 showed inhibition of SirT1-
dependent deacetylation of an acetylated p53 peptide. Interestingly, two of them also inhibited 
SirT2. Both SirT2 inhibitors were also able to inhibit the p53 deacetylation with IC50 values 
comparable to those determined in the MAL deacetylation assay. Moreover, we observed that 
the first 220 amino acids of the N-terminal region of SirT1 had an influence on the inhibitory 
effect of one inhibitor identified here. The potential activators failed to enhance the activity of 
SirT1 to deacetylate the p53 peptide. Surprisingly, one of them showed strong inhibition of 
SirT1 in this assay (Hill 2012) as well as inhibition of MAL deacetylation by ySir2 and SirT2. 
Subsequently, we determined the anticancer potential of the inhibitors identified in this study 
by different in vivo experiments with the lung cancer cell lines A549 and H1299. Three 
compounds that inhibited cell viability and proliferation of these cancer cells in a dose-
dependent manner were pursued in more detail. These three inhibitors induced an additional 
increase of apoptosis after combined treatment with the chemotherapeutic agent etoposide. 
We observed that the additional increase of apoptosis mediated by one of theses inhibitors 
was p53-dependent. In summary, this study has led us to identify one SirT1 inhibitor as well 
as two SirT2 inhibitors that showed antiproliferation potential and can be developed further 
for cancer therapy.  
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6. Zusammenfassung 
 
Sirtuine (SirT1-SirT7) sind die human Homologe der NAD+-abhängigen Histondeacetylase 
Sir2 aus der Bäckerhefe Saccharomyces cerevisiae. Seit der Beobachtung, dass die 
Überexprimierung von Sir2 in Hefen einen lebensverlängernden Einfluss hat, ist das Interesse 
an der Erforschung der Sirtuine enorm gewachsen. Jedes Sirtuin besitzt eine konservierte 
katalytische Domäne von etwa 275 Aminosäuren, sowie N-terminale und/oder C-terminale 
Sequenzen, die sich in ihrer Länge unterscheiden. Sirtuine sind vielversprechende 
Ansatzpunkte für die Behandlung zahlreicher Krankheiten, wie zum Beispiel Krebs, 
Stoffwechselkrankheiten, Diabetes und Alterung. Obwohl bereits einige Sirtuin-Inhibitoren 
und -Aktivatoren bekannt sind, ist der Mechanismus der Inhibition ungeklärt. Das Ziel der 
vorliegenden Arbeit war es, neue Sirtuin-Inhibitoren zu identifizieren und deren in vivo 
Potential als Chemotherapeutika zu untersuchen. Dazu wurde ein fluoreszenz-basierter Assay 
etabliert, bei dem ein Methyl-Aminocoumarin-Acetyllysine (MAL) als Substrat verwendet 
wurde, der für High-throughput Screening geeignet ist. Für die Identifizierung von SirT1-
Modulatoren wurden zwei Bibliotheken (500 und 18.000 Substanzen) gescreent, wobei 14 
potentielle Inhibitoren, sowie 12 potentielle Aktivatoren identifiziert wurden. Von diesen 
Inhibitoren zeigten 9 auch Inhibition von SirT1-abhängiger Deacetylierung eines acetylierten 
p53-Peptids. Des weiteren konnten zwei dieser Substanzen auch SirT2 inhibieren. Beide 
SirT2 Inhibitoren waren auch in der Lage, die p53 Deacetylierung zu inhibieren. Weiterhin 
haben wir beobachtet, dass die ersten 220 Aminosäuren der N-terminalen Region von SirT1 
einen Einfluss auf die Wirkung eines Inhibitors, der in dieser Arbeit identifiziert wurde, 
haben. Die potentiellen Aktivatoren zeigten keine Steigerung der SirT1 Aktivität bei der 
Deacetylierung des p53-Peptids. Erstaunlicherweise zeigte einer von ihnen starke Inhibition 
von SirT1 im p53 Deacetylierungs Assay (Hill 2012), sowie des ySir2 aus S. cerevisiae und 
von SirT2 mit MAL als Substrat. Im weiteren wurde das Potential der identifizierten 
Inhibitoren als Zytostatika mit unterschiedlichen in vivo Experimenten unter Verwendung der 
Lungenkrebszelllinien A549 und H1299 untersucht. Drei von ihnen, die der Lage waren, die 
Zellvitalität sowie die Zellteilung dosisabhängigen zu inhibieren wurden weiter untersucht. 
Interessanterweise verursachten sie einen zusätzlichen Anstieg der Apoptose nach 
kombinierter Behandlung mit dem Chemotherapeutikum Etoposide. Wir konnten zeigen, dass 
dieser Inhibitor-induzierte zusätzliche Anstieg der Apoptose zum Teil p53 abhängig war. 
Somit haben wir insgesamt einen SirT1-Inhibitor und zwei SirT2-Inhibitoren identifiziert, die 
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ein Antiproliferationspotential aufweisen und für Krebstherapien weiterentwickelt werden 
können.  
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7. Appendix 
 
In Saccharomyces cerevisiae a complex of Sir2, Sir3 and Sir4 are responsible for the 
formation of heterochromatin-like structure, which repress gene transcription in subtelomeric 
regions and the mating-type loci (HMR and HML) (Rusche et al. 2003). Silent chromatin 
assembles in two steps, nucleation and spreading. The Sir complex nucleates at silencers by 
associating of Sir3 and Sir4 with silencer-bound proteins such as Abf1, Rap1 and ORC. 
Spreading of the complex occurs through the Sir2-dependent deacetylation of acetyl groups 
from histones of adjacent nucleosomes, which creates additional binding sites for Sir3 and 
Sir4 (Hoppe et al. 2002; Luo et al. 2002; Rusche et al. 2002). The group of M. R. Gartenberg 
showed that a chimera (Sir3-Sir2243-562) containing Sir3 and the deacetylation core domain of 
Sir2 are able to silenced genes at the telomeres and both mating-type loci in a sir2Δ 
background (Chou et al. 2008). This suggests that the chimera Sir3-Sir2243-562 is able to bind 
at the silencers by Sir3 and spread by the Sir2-dependent deacetylation of histone tails. 
Furthermore, they generated a chimera (LexA-Sir278-252-Hos32-549-Sir2522-562) where the 
catalytic core domain of Sir2 is replaced by the Hos3 domain, a NAD+-independent 
deacetylase. They showed that this chimera is also able to silence HMR and HML in a sir2Δ 
background. These results suggest that the Sir2 N- and C-terminal region are sufficient to 
target a heterologous deacetylase for function within silent chromatin and that O-acetyl-ADP-
ribose (OAADPr), which is produced during the NAD+-dependent deacetylation reaction, are 
nor required for silencing in yeast (Chou et al. 2008). 
For the development of an in vivo screen for small modulators of SirT1, we sought to create 
comparable chimeras of SirT1 with ySir2 or Sir3, similar to those in (Chou et al. 2008). Our 
rationale was that if such chimeras provide SirT1-dependent silencing in yeast, an in vivo 
silencing assay could be used to screen for SirT1 inhibitors. In a first step, we verified 
silencing by the chimeric constructs provided by M. R. Gartenberg (Chou et al. 2008). 
Telomere silencing was measured with a URA3 reporter gene located at the telomere (TelVII-
L), which is expressed when silencing is abrogated. The Ura3 protein metabolizes 5-
fluoroorotic acid (5-FOA) to a toxic compound, such than Ura3 cells are unable to growth on 
5-FOA-containing media. Similar to the results of the group of Gartenberg, we observed 
telomeric silencing with the chimera Sir3-Sir2243-562 as well as Sir3-Hos32-549, but to a lesser 
extent. The silencing provided by the chimera LexA-Sir278-562 was comparable with the 
published results (Figure 7.1). We also observed slight silencing effects of the chimera LexA-
Sir278-252-Hos32-549-Sir2522-562, but this effect was not shown by the group of Gartenberg.  
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Figure 7.1: Sir2 chimeras induced telomeric silencing 
Repression of URA3 reporter was measured by growth on 5-FOA in strain AEY4017 (sir2Δ) transformed with 
empty vector or the respective plasmids. YM –URA and YM +URA plates provide loading and growth controls.  
 
HMR silencing was measured with a patch-mating assay, where the cells are not able to mate 
and form diploids with a tester strain of the opposite mating-type when silencing does not 
occur (described in 3.3.5). We observed that the chimeras Sir3-Sir2243-562, Sir3-Hos32-549 as 
well as LexA-Sir278-562 are able to silence HMR, which was similar to the results of (Chou et 
al. 2008) (Figure 7.2). However, we were not able to observe HMR silencing of the LexA-
Sir278-252-Hos32-549-Sir2522-562 chimera, unlike what was published in (Chou et al. 2008). The 
reason for this discrepancy is unclear. The chimera Sir3-Sir22-549 was also not able to silence 
the telomeres nor the HMR locus. This suggested that only the core domain of Sir2 (243-562) 
is able to induce silencing when it is attached to Sir3.  
 
Figure 7.2: Sir2 chimeras induced HMR silencing 
Patch mating-type assay was performed with the mating-type tester strain MATa and the yeast strain AEY4017 
(MATα, sir2Δ). HMR silencing was measured by selection of diploids on YM plates. 
 
Based on the result that the chimera Sir3-Sir2243-562 is able to silence telomeres as well as 
HMR, we sought create a similar chimera with the core domain of SirT1 in order to develop 
an in vivo screen for SirT1 modulators. For this approach, we cloned the chimeras Sir3-
SirT1240-500 as well as Sir21-252-SirT1240-500-Sir2522-562 into a yeast expression vector using 
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PCR-mediated plasmid gap repair (Figure 7.3). The fusions were chosen to be equivalent to 
those in Chou et al. 
 
Figure 7.3: Cloning strategies of the SirT1 chimeras 
The Sir2 (pAE231) and the Sir3 plasmid (pAE232) were digested by Stu I/Bgl II or by Eco47 II/Nco I. The core 
domain of SirT1 (244-498 aa) was amplified by PCR. The gene fusion was generated by PCR-mediated plasmid 
gap repair. 
 
With these two chimeras, we performed telomeric as well as HMR silencing to measure the 
ability of the SirT1 fusion to silence both loci. As shown in Figure 7.4, both chimeras were 
unable to silence at the telomeres in comparison to the positive control, wild-type Sir2, or the 
chimera LexA-Sir278-562. 
 
Figure 7.4: SirT1 chimeras did not induce telomeric silencing 
Repression of URA3 reporter was measured by growth on 5-FOA in strain AEY4017 (sir2Δ) transformed with 
wild-type Sir2 or the respective plasmids. YM –URA and YM +URA plates provide loading and growth 
controls.  
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Furthermore, both chimeras are also unable to silence the HMR locus (Figure 7.5), suggesting 
that the catalytic core domain of SirT1 is not sufficient to induce silencing at the telomeres or 
at the HMR locus in yeast. For this reason, we were unable to develop an in vivo screen for 
the identification of novel sirtuin modulators based on this approach. 
 
Figure 7.5: SirT1 chimeras did not induce HMR silencing 
Patch mating-type assay was performed with the mating-type tester strain MATa and the yeast strain AEY4017 
(MATα, sir2Δ). HMR silencing was measured by growth on YM plates (right side). The chimeras were placed as 
duplicate onto the agar as indicated by the scheme on the left site. Wild-type Sir2 and the LexA-Sir278-562 were 
used as positive control.  
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